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1. Introduction 
 
1.1. Cannabinoids 
 
Cannabinoids are the unique active compounds of the marijuana plant Cannabis sativa L. 
(Velasco et al., 2012). ∆9-Tetrahydrocannabidiol (∆9-THC) was the first cannabinoid isolated 
by Gaoni and Mechoulam (1964) from Cannabis and is also the main psychotropic plant 
cannabinoid (Howlett et al., 2002). Other phytocannabinoids are (-)-∆8-THC, (-)-trans-∆9-
Tetrahydrocannabidiol (∆9-THCV), cannabigerol, cannabinol and (-)-Cannabidiol (Pertwee, 
2008), with cannabinol and (-)-Cannabidiol not exerting any psychotropic effect (Mackie & 
Stella, 2006). Today ~70 cannabinoids produced by Cannabis sativa L. are known (Velasco 
et al., 2012). Since cannabinoids are hydrophobic, they were believed to exert their 
psychotropic and physiologic effects via direct insertion through the cell membrane and into 
the cell (Guzmán, 2003). In the late eighties, however, the development and labelling of THC 
analogues led to the discovery of a specific ligand system. (Di Marzo et al., 2004). In 1990, 
the first cannabinoid receptor (CNR1 = Cannabinoid receptor 1) was cloned, followed three 
years later by the second specific receptor (CNR2 = Cannabinoid receptor 2) (Pertwee, 
2008; Di Marzo et al., 2004). Cannabinoids binding as ligands to the two receptors can be, 
based on their structure and pharmacologic activity, classified into different groups (Howlett 
et al., 2002). Those cannabinoids that act as agonists on the cannabinoid receptors are 
assigned to four groups: The classical and the nonclassical cannabinoids, both deriving 
structurally from ∆9-THC (Howlett et al., 2002), the aminoalkylindoles, and the eicosanoids 
(Howlett et al., 2002). The classical cannabinoids refer to the natural phytocannabinoids and 
their synthetic analogues (e.g. HU210) (Howlett et al., 2002). The nonclassical cannabinoids 
differ from the classical cannbinoids by lacking the dihydropyran ring. The aminoalkylindoles 
differ structurally from but have pharmacological properties similar to THC. The well known 
(R)-(+)-WIN55212 belongs to this group (Howlett et al., 2002). The fourth group of ligands 
acting as agonists are the eicosanoids. All endogenous cannabinoid receptor agonists, called 
endocannabinoids, belong to this group, of which anandamide (AEA) and 2-
arachidonoyglycerol (2-AG) are the most intensely investigated ones (Howlett et al., 2002). 
The psychotropic effects induced by ∆9-THC are achieved by mimicking endocannabinoids 
(Guzmán, 2003).  
In addition to receptor agonists, which stimulate cellular response (Mackie, 2008) there are 
cannabinoids that act as antagonists or inverse agonists on the cannabinoid receptors, like 
for instance diarylpyrazoles (Howlett et al., 2002). The binding of an antagonist prevents 
agonists from receptor binding by interacting either with the active or the inactive receptor, 
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the inverse agonist binds to the inactive state of the receptor and leads to a decrease in 
basal receptor signalling (Mackie, 2008).  
 
1.2. Cannabinoid receptors 
 
The cannabinoid receptors received their name since they respond to cannabinoid drugs 
(Howlett et al., 2002). The two receptors are seven-transmembrane Gi/0 protein coupled 
receptors (Mackie and Stella, 2006). Whereas both have a high affinity for Gi, CNR1 has a 
higher affinity for G0 than CNR2 (McAllister and Glass, 2002). In addition, data exist 
indicating that CNR1 also binds to Gs (Demuth and Molleman, 2006). Both receptors show 
68% amino sequence homology within the transmembrane domain and 44% throughout the 
whole protein (Jean-Gilles et al., 2010). The amino acid (AA) length is 472AA for CNR1 and 
360AA for CNR2 (Howlett et al., 2002). Thus, the predicted size for CNR1 is 53kDa (Daaka 
et al., 1996) and 38kDa for CNR2 (Small-Howard et al., 2005). 
CNR1 is mainly expressed in the brain but also in peripheral nerve endings and extra neural 
sites, for example the spleen (Guzmán, 2003). In addition leukocytes were reported to 
express CNR1 (Mackie and Stella, 2006). CNR2 is mainly expressed in leucocytes. It is also 
called “peripheral” cannabinoid receptor due its abundance in thymus, tonsils, bone marrow 
and spleen and even retina (Croxford and Yamamura, 2005). Within peripheral blood 
mononuclear cells (PBMC), B lymphocytes show the highest CNR2 expression, the rank 
order being B lymphocytes, natural killer cells, monocytes/macrophages, neutrophils, CD8+ 
T lymphocytes, and CD4+ T lymphocytes (Mackie and Stella, 2006).  
Besides the two cannabinoid receptors, additional receptors were described to bind 
endocannabinoids. These include the transient receptor potential cation channel subfamily V 
member 1 (TRPV1), orphan G-protein coupled receptor (GPR) 55, GPR119 and GPR18 
(Velasco et al., 2012). TRPV1 is normally activated by heat or capsaicin, which is the active 
component of chilli peppers. The endogenous cannabinoid anandamide also was shown to 
bind to this receptor (Demuth and Molleman, 2006). Beside these receptors, cannabinoids 
also influence ligand-gated ion channels like the Serotonin (5-HT)3 receptor and Nicotinic 
acetylcholine receptors (nAChRs) (Demuth and Molleman, 2006).  
 
1.3. The endocannabinoid system 
 
Together with the endocannabinoid ligands, e.g. AEA and 2-AG, the two cannabinoid 
receptors constitute the endocannabinoid system (Guzmán, 2003). The first discovered 
endocannabinoid, AEA, is produced on demand by enzymatic cleavage of membrane lipid 
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precursors (Di Marzo et al., 2004) and inactivated by fatty acid amide hydrolase (FAAH) 
(Mackie and Stella, 2006). 2-AG is synthesized via phospholipase C (PLC) and diaglycerol 
lipase (DGL) pathway and inactivated by monoacylglycerol lipase (MGL) (Mackie and Stella, 
2006).  
Three additional endocannabinoids are proposed today: 2-arachidonyl-glyceryl ether (2-
AGE), O-arachidonoyl-ethanolamine (virhodamine) and N-arachidonoyl-dopamine (NADA) 
(De Petrocellis et al., 2004). All seem to be synthesized by different pathways, thus 
endocannabinoids constitute diverse compounds with different sites of action. 
One of the roles of the endocannabinoid system is modulation of neurotransmitter release 
(McAllister and Glass, 2002). In this case, endocannabinoids bind to CNR1, which is located 
on a presynaptic neuron and coupled to Ca2+ and K+ channels. This leads to depolarisation 
of the neuron membrane and inhibition of further neurotransmitter release (Guzmán, 2003). 
By this, endocannabinoids control physiological functions like movement, learning, cognition, 
appetite and emesis (Croxford and Yamamura, 2005) and seem to play a protective role by 
antagonizing central nervous system (CNS) excitoxicity and neuroinflammation (Jean-Gilles 
et al., 2010). In addition, the endocannabinoid system controls pain and functions in immune 
system modulation (Croxford and Yamamura, 2005). Regarding immune modulation, the 
injection of THC into mice resulted in suppression of cell-mediated immunity T helper cell 1 
and an increase of T helper cell 2 answer (Klein et al., 2003).   
Furthermore, endocannabinoids might play an important role in spermatogenesis, since a 
special isoform of CNR2 is predominantly expressed in human testis (Liu et al., 2009). 
 
1.4. Cannabinoid signalling 
 
Binding of cannabinoids to the cannabinoid receptors leads to signal transduction via the Gi/0 
pathway (Demuth and Molleman, 2006), resulting in inhibition of adenylyl cyclase and 
therefore in a decrease of cAMP (Demuth and Molleman, 2006). Without the binding of 
cAMP to the regulatory subunits of protein kinase-A (PKA), the catalytic subunits of this 
holoenzym stay inactive (Almeida and Stratakis, 2011). The decrease in PKA activity seems 
to have stimulatory effect on the mitogen-activated protein kinase (MAPK) pathway (Demuth 
and Molleman, 2006). This downstream signalling by activation of MAPK includes 
extracellular signal regulated kinase (ERK), p38 and c-jun-N-terminal kinase (JNK) 
(McAllister and Glass, 2002). The activation of the MAPK signalling by CNR appears to occur 
by activation of PI3K-Akt pathway (McAllister and Glass, 2002). Activation of 
phosphatidylinositol 3-kinase (PI3K) phosphorylates and thereby activates the MAP kinase 
kinase kinase (RAF), which in turn activates MAP kinase kinase (MEK), leading to activation 
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of MAP kinase and finally phosphorylation of cytoplasmic or nuclear proteins (Demuth and 
Molleman, 2006). Also, sphingomyelin hydrolysis and the release of ceramide after activation 
of RAF have been reported (Demuth and Molleman, 2006). 
Under certain conditions, CNR1 activation can lead to activation of Gs instead of Gi/0 
(McAllister and Glass, 2002). The activation of Gs results in the stimulation of adenylyl 
cyclase, this leads to the production of cAMP, which acts as a second messenger in the cell 
(Hein et al., 2006). In addition, CNR1 and CNR2 signalling influence intracellular calcium 
concentrations. While CNR1 was reported to interact with ion channels (Demuth and 
Molleman, 2006), CNR2 apparently does so poorly (McAllister and Glass, 2002). 
Furthermore, cannabinoid receptor ligation activates PLC, which leads to the generation of 
diacylglycerol and inositol triphopsphatase thus increasing calcium levels and resulting in the 
activation of protein kinase C (PKC). Besides the activation of transcription factors of the 
MAPK family, NF-κB might be activated and nitric-oxide (NO) levels increased by activation 
of the cannabinoid receptor (Klein et al., 2003). 
 
1.5. Clinical application of cannabinoids 
 
The plant-derived cannabinoid ∆9-THC was introduced into the clinics in 1988 as dronabinol 
(Marinol) followed by one of its synthetic analogues, nabilone (Cesamet) (Pertwee, 2008; Di 
Marzo et al., 2004). Nabilone is used for the suppression of nausea and vomiting during 
chemotherapy, Marinol for stimulation of appetite in AIDS patients (Pertwee, 2008). 
Furthermore, nabilone and THC showed promising results in the alleviation of tics in Tourette 
syndrome (Di Marzo et al., 2004). A cannabis extract, nabiximols (Sativex), has been 
approved in Canada and is tested in a Phase III clinical study against cancer-associated pain 
(Velasco et al., 2012). In addition, Sativex is available for the relief of central neuropathic 
pain and spasticity associated with multiple sclerosis (Karst et al., 2010).   
Also, (-)-Cannabidiol is a potential candidate for treatment of rheumatoid arthritis, since it 
was shown that this phytocannabinoid could suppress progression in collagen-induced 
arthritis in an animal model (Malfait et al., 2000). Rimonabant (SR141716A), a CNR1 
antagonist and inverse agonist, was used in treating obese persons and was also successful 
in doubling the abstinence rate in smokers (Di Marzo et al., 2004). Dexanabilon (HU-2111), a 
synthetic cannabinoid, is tested as neuro protective compound in cases of severe head injury 
(Di Marzo et al., 2004).  
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1.6. Role of cannabinoids in cancer 
 
Cannabinoids have been reported to block angiogenesis, invasion and metastasis, inhibit 
cancer cell proliferation and induce cancer cell death by apoptosis (Velasco et al., 2012; 
Guzmán, 2003).  
Angiogenesis is inhibited by blocking the activation of the vascular endothelial growth factor 
(VEGF) pathway (Velasco et al., 2012). By acting on matrix metalloproteinase 2 (MMP2) and 
its inhibitor, tissue inhibitor of matrix metalloproteinases 1 (TIMP1), cannabinoids inhibit 
adhesion, migration and therefore invasiveness of cancer (Velasco et al., 2012). Cell death is 
induced by de novo synthesis of ceramide which induces endoplasmatic reticulum (ER) 
stress leading to Akt inhibition of autophagy and intrinsic mitochondrial apoptosis (Velasco et 
al., 2012). Inhibition of Akt also leads to the activation of p27 and p21 resulting, via cyclin-
dependent kinase (CDK) and retinoblastoma (RB), in cell cycle arrest and thus in apoptosis 
(Velasco et al., 2012). Through activation of the MAPK pathway, JNK induces apoptosis and 
p38 anti-proliferative effects (McAllister and Glass, 2002). Under normal conditions, 
activation of ERK leads to cell proliferation; however, prolonged ERK activation induced by 
cannabinoids mediates cell cycle arrest and cell death (Guzmán, 2003).  
Thus, tumour cell proliferation decreased in melanoma cells by the cannabinoids   
WIN-55,212-2 and JWH133 in vivo. Furthermore, incubation with THC or WIN-55,212-2 
resulted in a dose dependent anti-proliferative effect on melanoma cells but not on a non-
tumorigenic line of melanocytes (Blázquez et al., 2006). It was shown in melanoma cells that 
inhibition of Akt contributes to the anti-proliferative effect of cannabinoids, whereas ERK, 
JNK, and p38 were not significantly involved (Blázquez et al., 2006).  
In a human prostate cancer cell line (PC-3), R-(+)-Methanandamide was reported to exert an 
anti-proliferative effect and to induce dose dependent decrease in cell viability (Olea-Herrero 
et al., 2009). These effects were induced by de novo synthesis of ceramide, increase of JNK 
phosphorylation, and decrease in Akt phosphorylation (Olea-Herrero et al., 2009). The 
incubation of acute lymphoblastic leukemia (ALL) primary cells with THC at a concentration 
of 5µM resulted in a significant reduction of viability (McKallip et al., 2002). Cell lines of 
mantle cell lymphoma (MCL) and the chronic lymphocytic leukemia cell lines MEC-1 and 
MEC-2 showed apoptosis and cell death after incubation with R-(+)-Methanandamide 
(Gustafsson et al., 2008). This effect was abrogated by treatment with the CNR1 and CNR2 
antagonists SR141716 and SR144528 (Gustafsson et al., 2008). Besides the cytotoxic effect 
of cannabinoids, it was found that the CNR1 and CNR2 are higher expressed in the majority 
of non-Hodgkins lymphomas than in control tissues (Gustafsson et al., 2008). 
1. Introduction 
6 
1.7. Chronic Lymphocytic Leukemia 
 
Chronic lymphocytic leukemia (CLL) is a monoclonal proliferation of B cells (Hallek et al., 
2008) belonging to the non-Hodgkin lymphomas (Müller-Hermelink et al., 2008) and the most 
prevalent leukemia of adults in Western countries (Müller-Hermelink et al., 2008). 
Incidence rate is 2-6 cases per 100.000 persons per year, increasing with age (Müller-
Hermelink et al., 2008). At the mean age at diagnosis, 65, the incidence rate reaches 
12,8/100.000 with males being more frequently affected than females (ratio of 1,5-2:1) 
(Müller-Hermelink et al., 2008). Concerning the inheritability of CLL, it has the highest genetic 
predisposition of all hematologic neoplasias (Müller-Hermelink et al., 2008). The overall risk 
is 2-7 times increased in first degree relatives of CLL patients (Müller-Hermelink et al., 2008). 
CLL is diagnosed when there is an increase in clonal B cells with at least 5x109 B 
lymphocytes per litre peripheral blood (Hallek et al., 2008). Further clinical parameters are: 
Lactate dehydrogenase (LDH) elevation, bone marrow (BM) infiltration, lymphocyte doubling 
time (LDT), CD23, ß2-microglobulin and thymidine kinase (TK) (Mozaheb et al., 2012).  
Symptoms of this disease are fatigue, enlargement of spleen and liver, lymphadenopathy, 
infections, and autoimmune haemolytic anaemia (Müller-Hermelink et al., 2008).  
For clinical staging two systems are established. In North America, mainly the Rai 
classification system is used (Sagatys and Zhang, 2012). It includes five stages with 
lymphocytosis, anemia and thrombocytopenia as parameters (Sagatys and Zhang, 2012). In 
Europe, the Binet staging system is more common (Sagatys and Zhang, 2012). This system 
distinguishes three stages with haemoglobin level, platelet count and number of involved 
areas as discriminators (Sagatys and Zhang, 2012). The clinical course of the disease is 
heterogeneous (Malavasi et al., 2011). Of unclear reasons, patients of the same stage 
progress differently (Mozaheb et al., 2012). To better discriminate between cases and for 
better stratification of patients, more refined prognostic markers are needed.  
A number of prognostic markers have been established so far. An important marker is the 
mutation status of the immunoglobulin heavy chain (IGH) V gene for which an unmutated 
status predicts a worse disease course (Müller-Hermelink et al., 2008). In more than 80% of 
all CLL cases cytogenetic lesion can be found (Hallek et al., 2008). The most common 
lesions are: deletion at 13q14.1, trisomy of chromosome 12, deletions at the long arms of 
chromosomes 11 or 6 and/or the short arm of chromosome 17 (Hallek et al., 2008). A worse 
prognosis is given for the chromosomal lesions del11q22-23, del17p and del6p (Müller-
Hermelink et al., 2008). The alteration of the p53 gene is not only associated with a poor 
prognosis but also with resistance to treatment and is a consequence of the deletion on 
chromosome 17p (Sturm et al., 2003). 
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Furthermore the expression of zeta-chain associated protein kinase-70 (ZAP-70) and the 
CD38 surface protein convey worse prognosis (Müller-Hermelink et al., 2008). 
CLL cells are small, mature lymphocytes with a narrow border of cytoplasm and a nucleus 
with partially aggregated chromatin (Hallek et al., 2008). On the surface, CLL cells co-
express CD5 and B-cell surface antigens CD19, CD20 and CD23, while immunoglobulin (Ig), 
CD20, and CD79b show lower expression compared to normal B cells (Hallek et al., 2008). 
CLL cells accumulate in lymphoid organs, BM and peripheral blood (Granziero et al., 2001). 
Circulating CLL cells are long-lived and arrested in G0 early G1 phase of cell cycle 
(Granziero et al., 2001), but CLL is not a static disease (Messmer et al., 2005). Deuterium, a 
nonradioactive isotope that labels newly synthesized DNA of dividing cells, was administered 
to nineteen CLL patients (Messmer et al., 2005). It could be shown that CLL has slow but 
steady dynamics, with a birth rate of leukemic cells in CLL patients between 0,1% to over 1% 
of the clone per day (Messmer et al., 2005). As proliferation hotspots for CLL cells specific 
micro-environmental structures were reported (Damle et al., 2010): These structures 
(pseudofollicles or proliferation centres), mainly consisting of CLL cells, T cells, and follicular 
dendritic cells, are found in lymph nodes (LN) and BM (Damle et al., 2010).  
CLL cells seem to be antigen experienced (Chiorazzi and Ferrarini, 2011) raising questions 
regarding the origin of CLL cells. One hypothesis postulates a two cell origin for mutated and 
unmutated IGHV CLL cells, respectively (Chiorazzi and Ferrarini, 2011). In this model Ig 
unmutated CLL cells derive from pre-germinal center B cells and Ig mutated CLL cells derive 
from cells that passed the germinal center (GC) (Rosenwald et al., 2001). According to 
another model, both M and UM CLL cells derive from marginal zone B cells (Chiorazzi and 
Ferrarini, 2011). In a study using Lymphochip cDNA microarrays it could be shown that B cell 
activation genes are differently expressed between Ig mutated and Ig unmated CLL cells, 
although both subgroups share a characteristic gene expression signature (Rosenwald et al., 
2001), thus favouring the one cell of origin theory. Comparing gene expression profiles of 
CLL cells with normal B cell subpopulations, CLL cells appeared to be more closely related 
to memory B cells (post GC) than to pre-GC B cells, CD5+ B cells, germinal centre 
centroblasts and centrocytes (Klein et al., 2001). Still, CLL cells differ from memory B cells in 
the expression of genes encoding for functions in proliferation, adhesion, cytokinesis and 
apoptosis (Klein et al., 2001). Due to the accumulation of the CLL cells, patients suffer from 
disease-specific complications. T cells in CLL patients show a frequent oligoclonality of CD4+ 
and CD8+ T lymphocytes with an impaired function (Dearden, 2008). Neutrophils and 
monocytes are also defective in their function (Dearden, 2008). About 70% of the patients 
develop hypogammaglobulinemia within seven years of diagnosis. Thus, most CLL patients 
show a reduction in Ig level, correlated to the frequency and severity of bacterial infections 
(Dearden, 2008). In addition, 10% to 25% of the patients develop autoimmune complications 
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with autoimmune haemolytic anemia (AHA) as the most common form of autoimmune 
disorder (Dearden, 2008). CLL patients with early-stage disease are often asymptomatic and 
therefore monitored without therapy (Hallek et al., 2008). For AHA therapy, prednisolone is 
used (Dearden, 2008). In case of progression, chlorambucil alone or in combination with 
steroids was standard therapy (Reynolds et al., 2012). Today it is still administered to elderly 
patients as front-line therapy (Lu and Wang, 2012) since this regimen is better suited for 
patients with comorbidities. Although in trials fludarabine yielded a higher response rate 
compared to chlorambucil as initial treatment (Reynolds et al., 2012) for proper impact of 
fludarabine an intact p53 gene is necessary (Sturm et al., 2003). Other used 
chemotherapeutics are cladribine, cyclophosphamide, mitoxantrone, and bendamustine (Lu 
and Wang, 2012). In addition to chemotherapy some monoclonal antibodies are available, 
which are often used in combination with chemotherapy (Lu and Wang, 2012). Rituximab 
was the first approved antibody for treatment of cancer targeting CD20 (Lu and Wang, 2012). 
Alemtuzumab targets the CD52 cell-surface antigen, and ofatumumab (anti-CD20) has been 
approved for CLL patients refractory to fludarabine and alemtuzumab (Lu and Wang, 2012). 
Furthermore, new compounds, such as lenalidomide, high-dose methylprednisolone, cyclin-
dependent kinase inhibitors and several kinase inhibitors of B cell receptor signalling 
pathways are being tested (Lu and Wang, 2012). Standard chemoimmunotherapy is today 
the combination of fludarabine, cyclophosphamide and rituximab (Foon and Hallek, 2010). 
However, when patients that do not response to chemotherapy, allogeneic hematopoetic 
stem cell transplantation is the only therapteuic option left (Hallek et al., 2008). 
 
1.8. Cell-cell interaction and microenvironment in CLL 
 
The microenvironment is a compilation of accessory cells that interacts with malignant cells 
and promotes tumour growth and drug resistance (Burger et al., 2009). Especially in CLL the 
microenvironment seems to protect cancer cells from spontaneous and drug-induced 
apoptosis (Burger et al., 2009). This protection relies on the secretion of chemokines by 
stromal cells and the expression of adhesion molecules (Burger et al., 2009), but also B cell 
receptor (BCR) stimulation by stroma-derived antigens contribute to the protective effect 
(Binder et al., 2010). The stroma derives from so called mesenchymal stromal cells (MSCs) 
(Seke Etet et al., 2012). These are adult multipotent non-hematopoietic stem cell precursors 
which support the maintenance and engraftment of hematopoietic stem cells (Seke Etet et 
al., 2012). Besides MSCs, nurse like cells (NLCs) are found in the spleen and lymphoid 
tissue of patients (Burger et al., 2009). It was shown that these NLCs differentiate from blood 
monocytes when cultured together with CLL cells (Burger et al., 2009). In vitro, CLL cells 
undergo spontaneous apoptosis when kept in culture alone, however, coculturing these cells 
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with feeder cells, stromal cells, NLC or similar, prolongs cell survival (Kurtova et al., 2009). 
This prosurvival effect includes different factors. Thus, MSC express Notch receptor plus 
ligands and Notch stimulation had a pro-survival impact on CLL (Seke Etet et al., 2012). In 
addition the Wnt signalling (Seke Etet et al., 2012) and the stromal produced hedgehog 
proteins exert a survival effect in CLL (Hegde et al., 2008). Concerning soluble factors, CLL 
cells can express receptors for pro-angiogenic factors as the vascular endothelial growth 
factor receptor (VEGFR) 1 and 2, the signalling through these receptors prolongs cell 
survival (Deaglio and Malavasi, 2009). In receptor ligand pairing, CD40L/CD40 and 
CD38/CD31 interaction contribute to survival (Deaglio and Malavasi, 2009). Also chemokines 
like CXCL13, CCL19 and CCL21 exert a survival supporting function by controlling migration 
(Deaglio and Malavasi, 2009). Furthermore, the interaction between CLL cells and their 
microenvironment is not only in one direction. CLL cells can secrete angiogenic cytokines 
and thus modulate the local microenvironment (Lanasa, 2010).  
From among all those factors supporting CLL cells, most attention was given to the 
chemokine CXCL12, also called SDF-1 (stromal derived factor-1) (Burger and Kipps, 2006). 
CXCL12 is a highly conserved chemokine supporting close cell to cell contact between B cell 
precursors and the protective stroma (Burger and Kipps, 2006). CXCL12 attracts naive and 
memory, but not germinal centre B cells (Bleul et al., 1998). CXCL12 is secreted by stromal 
cells and NLCs (Burger and Kipps, 2006) so that CLL cells are attracted to niches where 
these feeder cells provide them with pro-survival stimuli (Burger et al., 2009). This 
chemokine signals through the chemokine receptor CXCR4 (Burger and Kipps, 2006). Like 
all chemokine receptors, CXCR4 belongs to the 7-transmembrane G protein coupled 
receptor (GPCR) and is highly expressed in CLL (Burger and Kipps, 2006). It is also the most 
intensely studied chemokine receptor in CLL. This is due to that antagonizing the 
CXCR4/CXCL12 axis with a specific CXCR4 specific antagonist, AMD3100 (plerixafor) was 
shown to sensitize CLL cells to drug-induced apoptosis in coculture (Stamatopoulos et al., 
2011). AMD3100 is a bicyclam molecule that selectively and reversibly antagonizes the 
binding of CXCL12 to its receptor CXCR4 (Pusic and DiPersio, 2010). This compound is 
already approved for hematopoietic stem and progenitor cell mobilisation in patients with 
non-Hodgkin`s lymphoma (NHL) and there are studies that use AMD3100 as therapy to 
stimulate re-vascularization after acute tissue injury (Pusic and DiPersio, 2010). Concerning 
CLL, AMD1300 is tested as sensitizing agent in patients treated with rituximab (Pusic and 
DiPersio, 2010). 
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1.9. Cannabinoids and the microenvironment 
 
Concerning the function of cannabinoids in microenvironment it could be shown that they 
influence chemotaxis in different cells. Thus, BM cells from mice migrate toward 2-AG in a 
dose dependent manner (Patinkin et al., 2008). Furthermore, with CNR1 stable transfected 
human embryonic kidney 293 cells migrate toward the cannabinoid agonists HU-210, 
WIN55212-2 and anandamide (Song and Zhong, 2000) and splenic mouse lymphocytes 
migrate toward 2-AG, which could be inhibited by SR144528 (Tanikawa et al., 2007). Also B 
cell trafficking seems to be influenced by cannabinoids. The cannabinoid receptor agonist 
WIN55-212,2 induces migration of splenic lymphocytes and inhibits CXCL12 induced 
migration in B lymphocytes (Tanikawa et al., 2011).  
Cannabinoids do not only induce migration. In macrophages, treatment with THC results in 
the inhibition of migration of murine peritoneal macrophages to CCL5 in vivo and in vitro. 
This effect was reversed by the CNR2 antagonist SR141716A (Raborn et al., 2008). CXCL12 
induced chemotaxis of Jurkat cells (T cell line) and primary CD4+ as well as CD8+ T 
lymphocytes was inhibited by incubation with an CNR2 agonist (Ghosh et al., 2006). A 
similar result was also found by Coopman et al., where JWH133 and 2-AG inhibited CXCL12 
induced chemotaxis of activated T lymphocytes (Coopman et al., 2007). However, resting 
and activated T lymphocytes did not migrate towards both cannabinoids. (Coopman et al., 
2007). In the case of breast cancer a CNR2 agonist inhibited the migration of the MCF7 cells 
and the downstream signalling of the CXCR4 in vivo in a breast cancer mouse model 
(Nasser et al., 2011). The influence of cannabinoids on CLL migration still needs to be 
investigated.  
2. Aim of the study 
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2. Aim of the study 
 
Cannabinoids were shown to exert pro-apoptotic and anti-proliferative effects in solid 
tumours and in NHL by binding to the CNR1 and CNR2 receptor. Furthermore, various 
studies reported that cannabinoids inhibit the migration toward CXCL12 in T lymphocytes 
and cell lines by interfering with the CXCL12/CXCR4 axis. This axis is described to be a 
responsible factor in microenvironment induced CLL treatment resistance.  
Therefore the aims of the study were: 
• To evaluate retrospectively the mRNA expression pattern of CNR1 and CNR2 within 
CLL patients. 
• To investigate the potential of the cannabinoid receptor expression as an additional 
prognostic maker.  
• To test whether protein expression levels of CNR1 and CNR2 follow the mRNA 
expression. 
• To evaluate the cytotoxic effect of CNR1 and CNR2 specific agonists and antagonists 
on CLL specific and other cancer cell lines and to see whether mRNA receptor 
expression correlates with sensitivity towards the compounds. 
• To test the cytotoxic effect of cannabinoids on primary CLL cells incubated in 
suspension and in coculture with the mouse fibroblast line M2-10B4 with the 
compounds and to see whether mRNA receptor expression correlates with sensitivity. 
• Compare the sensitivity of primary CLL cells with peripheral blood mononuclear cells 
(PBMC) from healthy donors (HD) to evaluate the potential of these cannabinoids as 
therapeutic substances. 
• To test the impact of cannabinoids on migration of CLL cells toward CXCL12 and 
compare their impact with a CXCR4 inhibitor. 
2. Aim of the study 
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2.1. Cannabinoids used in this study 
 
The following compounds were used as agonists, antagonist and inverse agonist in the 
experiments of this study:  
(R)-(+)-Methanandamide is an analogue of the endocannabinoid AEA and a selective agonist 
for CNR1 (Pertwee, 2006). It was synthesized in 1994, its affinity for CNR1 is lower than that 
of its natural counterpart AEA but it has a stronger cannabmimetic effect and shows a higher 
stability to aminopeptidase hydrolysis than AEA (Abadji et al., 1994). 
Another anandamide analogue that was used is ACEA. This compound was synthesized 
1999 by Hillard et al. and was characterized as a high affinity agonist for CNR1 and only low 
affinity for CNR2 (Hillard et al., 1999). Its high affinity for CNR1 was shown in a bioassay 
where rat cerebellar membranes (expressing CNR1) were incubated with radiolabelled 
[3H]CP55940 that saturably bind to CNR1 and ACEA competed for this [3H]CP55940 binding 
(Hillard et al., 1999). 
As CNR2 agonist, JWH133 was used. This is a ∆9-THC analogue, therefore a classical 
cannabinoid and a selective CNR2 agonist (Pertwee, 2006). Its effect on macrophage IL-12 
production can be blocked by a CNR2 but not by a CNR1 antagonist (Correa et al., 2005).  
In contrast to most other studies, this study also evaluated the cytotoxic effects of 
antagonists, for which AM251, AM630, and (-)-Cannabidiol were used.  
AM251 is an analogue of SR141716A, which belongs to the diarylpyrazoles group of 
cannabinoids and is a selective CNR1 antagonist (Howlett et al., 2002; Lan et al., 1996).  
As an antagonist of CNR2, AM630 was tested. Its antagonistic effect on cannabinoid 
receptor agonist was shown in isolated vas deferens of mice (Pertwee et al., 1995). 
Furthermore AM630 is also described to act as an inverse agonist on CNR2 and as a weak 
agonist on CNR1 (Ross et al., 1999). In addition it is also presumed to act as a weak inverse 
agonist on CNR1 (Landsman et al., 1998).  
The last compound used in the study was (-)-Cannabidiol. Beside the ∆9-THC it is a plant 
derived compound without psychoactive effects (Guzmán, 2003). It can act as an inverse 
agonist on the CNR2, it antagonizes CNR1 agonists in vitro (Thomas et al., 2007) and it also 
acts as a weak agonist on the vanilloid receptor (Costa et al., 2004). 
3. Methods 
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3. Methods 
 
A list with all materials, chemicals inclusive manufactures name can be found in the appendix 
 
3.1. Patients and healthy donors 
 
Peripheral blood samples were collected from 108 consecutive patients diagnosed with CLL 
at the Division of Hematology and Hematology, General Hospital, Vienna. All patients and 
the four healthy volunteers included in the study signed informed consent according to the 
Declaration of Helsinki (Ethics Committee Nr: 1011/2012). Of the 108 patients, 102 were 
used for the investigation of mRNA expression levels. The additional 6 patients were used in 
FACS analysis, migration assays and in experiments using a microenvironmental model for 
drug treatment. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll 
separation; cells were stored viable in liquid nitrogen. For protein analyses, 1x106 PBMCs 
were centrifuged 5minutes 5000rpm at 4°C, supernatant was discarded and cell pellets were 
stored at -80°C. For RNA extraction, primary cells were stored at -80°C in TRIzol according 
to the manual. B lymphocytes from healthy donors were isolated from the PBMCs using the 
EasySep™ Human B Cell Enrichment Kit without CD43 Depletion following the 
manufacturer´s protocol. 
 
3.2. Cell lines cell culture 
 
The cell lines MEC-1, MEC-2, JURKAT, A-549, and M2-10B4 were cultured at a density of 
5x105 – 1x106 cells/ml under standard conditions (95% humidity, 5% CO2, 37°C). MEC-1, 
MEC-2, JURKAT and M2-10B4 were kept in RPMI1640 whereas A-549 was cultured in 
DMEM, both media containing in addition 10% FCS and 1% Penicillin / Streptomycin. A-549 
and M2-10B4 cells were propagated by removing the medium, rinsing with PBS, and 
incubation with 4x Trypsin-EDTA for three minutes at 37°C prior to dilution with complete 
medium. 
All experiments were performed using the culture medium without phenol red. 
 
3.3. Primary cells cell culture 
 
Cells were thawed 24h before experiment. RPMI1640 + 20% FCS were warmed to 37°C in a 
50ml Falcon. An aliquot of the warm medium was carefully added to the cells and cells were 
resuspended. Thawed cells were transferred to the 50ml Falcon with the rest of warm 
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medium. This step was repeated until all cells were thawed. Cells were centrifuged for 10min 
at 1000rpm at room temperature (RT). Supernatant was discarded and pellets resuspended 
in RPMI1640 + 20% FCS without phenol red, transferred to a small culture flask and 
incubated over night at 37°C under standard conditions. All experiments were performed 
using culture medium without phenol red. After 24h cells were transferred to a 50ml Falcon, 
centrifuged for 10minutes at 1000rpm at RT, pellets were dissolved in RPMI1640 without 
phenol red and cells counted using a counting chamber before the preparation of 
experiments. 
 
Cell counting: 
 
The cover glass was placed on the counting chamber. Cell suspension was diluted 1:1 with 
0,4% Trypanblue. For primary cells, the cell suspension was additionally diluted 1:10 in 
RPMI1640 et al. The dilution was introduced into the counting chamber until the mirrored 
surface was covered. Cells in three of the outer four big squares were counted. 
Cell count per ml was calculated by: 
Mean cell count x dilution factor x 10.000 = cells/ml 
 
3.4. RNA extraction 
 
Cell lines: Cells from the cell culture were counted and 3x106 cells were transferred to 15ml 
Falcon tubes. After centrifugation for 10minutes at 1000rpm at RT, supernatants were 
discarded, and pellets were dissolved in 1ml TRIzol and transferred to a 2ml reaction tube.  
 
CLL samples: Cell aliquots stored frozen in TRIzol were used (see chapter 3.1.). 
 
Healthy donors: CD19 sorted cells from two male and two female samples were pooled, 
respectively, to obtain sufficient material for RNA extraction. Samples had been stored at -
80°C in 1ml TRIzol (see chapter 3.1.). 
 
Samples were incubated at RT for 5minutes. Then 200µl of chloroform was added and the 
tube was vortexed for 15seconds. After 3minutes incubation at RT, samples were centrifuged 
at 15 000rpm for 15minutes at 4°C. The aqueous phase (RNA Phase) was transferred to a 
safe lock reaction tube and 500µl of isopropanol was added for RNA precipitation. The 
samples were incubated at RT for 10minutes, followed by a centrifugation step of 15 000rpm 
for 10minutes at 4°C. The supernatant was removed, 1ml of 75% ethanol was added for 
washing, and samples were centrifuged at 12 000rpm 5minutes at 4°C. This washing step 
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was repeated. Ethanol was discarded and the pellets became air-dried. Finally, the pellet 
were dissolved in 10µl DEPC water and incubated at 55°C for 10minutes. The amount of 
isolated RNA and the A260/A280 ratio was measured using NanoDrop 8000 and the 
software NanoDrop 8000 V. 2.1.0. following the manufacturer’s protocol. Until cDNA 
synthesis samples were stored at -80°C. 
 
3.5. cDNA synthesis 
 
Two µg of RNA was used for cDNA synthesis in maximal 5µl of reaction volume. Two 
Mastermixes were prepared in separate 2ml reaction tubes. All reagents were stored on ice.  
 
Mastermix 1 
For one sample: 
0,5µl Oligo (dT) 15 Primer 
10,5µl Aqua bidest 
Mastermix 1 was vortexed, 11µl were transferred to 0,5ml reaction tubes. Two µg RNA was 
added and the tubes were incubated at 72°C for 5minutes.  
 
Mastermix 2 
For one sample: 
5µl 5x Reaction Buffer 
4,125µl Aqua bidest 
1,25µl dNTPs (10mM) 
0,625µl RNAsin Plus 
1µl M-MLV Reverse transcriptase 
Mastermix 2 was shortly mixed and 12µl were added to the samples. The samples were 
incubated for 1h at 42°C. 
Until Real time PCR, the cDNA was stored at -20°C. 
 
3.6. Real time PCR 
 
Real time PCR was carried out using TaqMan® Gene Expression Assays on demand 
CNR1: Hs00275634_m1 FAM reporter labelled 
CNR2: Hs00361490_m1 FAM reporter labelled 
ß-actin Human ACTB (#4326315E) VIC reporter labelled 
These assays contain primer and probe.  
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Real time PCR mix for one cDNA sample 
11,4µl Aqua bidest 
0,6µl primer assay 
12,0µl TaqMan® Universal Master Mix  
 
Reagents were mixed and 24µl were transferred to a semi-skirted 96-Well PCR Plate. 1µl of 
cDNA was added for a reaction volume of 25µl. 
Samples were done in duplicates; two wells without cDNA (only mastermix) were used as 
negative control. After sealing the plate surface with a cover film, the plate was placed in the 
ABI Prism 7000 Sequence Detector. The instrument was used following manufacturer's 
instructions; runs were analyzed using the ABI Prism 7000 SDS Software.  
 
Cycle protocol 
1 cycle: 2 minutes 50°C 
1 cycle: 10 minutes 95°C 
40 cycles: 15 seconds 95°C and 1 minute 60°C 
 
For calculation of mRNA expression, the ∆∆Ct-method was used (Livak and Schmittgen, 
2001). ß-actin was chosen as housekeeping gene. Ct values of ß-actin were subtracted from 
the Ct values of CNR1 and CNR2 resulting in the ∆Ct value. The ∆∆Ct was obtained by 
subtracting the mean ∆Ct value of the two CD19 sorted healthy donor pools from the ∆Ct of 
the patients’ samples. By logarithmic transformation using the formula 2∆∆Ct, the relative fold 
increase of CNR1 and CNR2 mRNA expression was calculated. 
 
3.7. Protein isolation 
 
A-549 and JURKAT cells were pelleted directly from cell culture using 5x106 and 10x106 
cells, respectively, and adding 150µl RIPA Buffer complete. Patient samples containing 
50x106 to 100x106 cells were mixed with 500µl to 1000µl RIPA Buffer complete, depending 
on pellet size. 
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RIPA Buffer complete 
RIPA Buffer 
NaCl (in MilliQ)  150mM 
Tris-HCl pH7,4 (in MilliQ)        50mM 
Na-deoxycholate (in MilliQ)        0,5% 
EGTA (1M in NaOH)         2mM 
EDTA pH7,4 (in MilliQ)        5mM 
NaF (in MilliQ)         30mM 
ß-Glycerophosphate pH7,2 (in MilliQ)      40mM 
Tetrasodium Pyrophosphate (in MilliQ)      10mM 
Benzamidine (in MilliQ)        3mM 
Nonidet P-40          1% 
 
Adjusted to pH7,4 and filled up to 95ml with MilliQ water 
 
RIPA Buffer complete 
RIPA Buffer           1,9ml 
200mM Na-Orthovanadate (in MilliQ)      20µl 
25x Complete (Protease Inhibitor Cocktail Tablets in MilliQ)   80µl 
 
After dissolving the pellets in freshly prepared RIPA Buffer complete, samples were vortexed 
for 10seconds and incubated on ice for 5minutes. These two steps were repeated followed 
by a centrifugation step at 12 500rpm at 4°C for 30minutes. Finally the supernatant was 
transferred to a 1,5ml reaction tube. 
The protein concentration was determined by Pierce BCA Protein Assay Kit according to the 
manufacturer’s instructions. 
 
3.8. SDS PAGE 
 
The Mini-PROTEAN Tetra Electrophoresis System was assembled according to the manual 
using 1mm spacer. Then, a 10% separation gel was filled into the gel sandwich and overlaid 
with Aqua bidest. After polymerization, a 4% stacking gel was prepared. The Aqua bidest 
was removed from the sandwich and the stacking added on top of the separation gel. Finally, 
a 10 well comb was added. When the stacking gel was polymerized the gel sandwiches were 
inserted into the electrophoresis chamber. One x running buffer was added to the chamber. 
Finally, the combs were carefully removed and the samples were added into the wells.  
 
10% seperation gel 
 
MilliQ water          8ml  
30% A/B Bis-Acrylamid        6,7ml  
1,5M Tris-HCl pH 8,8         5ml  
10% SDS          200µl  
10% APS (in MilliQ)         100µl 
Temed           10µl 
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4% stacking gel 
MilliQ water          7,46ml  
30% A/B Bis-Acrylamid        1,67ml  
0,5M Tris-HCl pH6,8         3,15ml  
10% SDS          125µl  
10% APS (in MilliQ)         125µl  
Temed           12,5µl  
 
10x running buffer 
Tris base          30,3g  
Glycine          144,2g 
SDS           10,0g 
Add MilliQ water up to 1000ml 
Make a 1:10 dilution for 1x running buffer 
 
For the sample preparation three parts of the sample was mixed with one part of the 4x 
protein loading buffer. 
 
4x Protein loading buffer 
Tris-HCl pH 6,8         125mM 
Glycerol          50% 
SDS           4% 
Orange G (w/v)         0,2% 
Add MilliQ water up to 15ml 
 
Before adding the samples, the loading buffer was diluted 1:10 with ß-mercaptoethanol. 
Then the samples were incubated at 95°C for 5minutes. As controls, recombinant proteins 
for CNR1 and 2 were used which were not heat incubated before loading.  
 
CNR1 (Human) Recombinant Protein [# H00001268-G01 ABNOVA]; MW: 52,9kDa 
CNR2 (Human) Recombinant Protein [# H00001269-G01 ABNOVA]; MW: 39,7kDa  
(see Datatsheets) 
 
Sixty µg of the samples, 0,19µg of recombinant CNR1 and 0,1µg of recombinant CNR2 were 
loaded into the slots. Two µl of peqGOLD Protein-Marker IV was added to the first slot. Two 
gels per chamber ran at 60V, 35mA for 20minutes and 50minutes at 130V and 60mA. 
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3.9. Western blot 
 
For Wet-Western blot the Mini Trans-Blot® Electrophoresis Transfer Cell was used. Before 
assembly, transfer buffer was freshly prepared and stored at 4°C. 
 
Transfer buffer 
Glycine          11,2g 
MilliQ water           745ml 
1M Tris pH 8,3         50ml 
10% SDS          5ml 
Methanol          200ml 
 
For each gel, four pieces of Gel Blot Paper and one piece of PVDF Immobilon-FL   
Transfermembran (pore size 0,45µM) was cut to gel size. After SDS PAGE, the gels were 
put into transfer buffer for 10minutes. The PVDF membrane was activated for 15seconds in 
methanol and transferred to transfer buffer and incubated for 5minutes. After assembly, 
samples were blotted for 2hours at 40V and 500mA at 4°C. 
Then, membranes were blocked over night in 5% non-fat dry milk in PBS at 4°C. Primary and 
secondary antibodies were diluted in PBS + 0,1% Tween20 with 10% NaN3 (1:500).  
 
Primary antibody 
Anti-CNR1 polyclonal Antibody [Thermo Scientific #PA1-745] diluted 1:1000 
As described in the Datasheet: 
Host rabbit; Immunogen: Aminoacids 1-77; 
Detects a Band at ~60kDa and lighter Bands at ~23kDa, ~72kDa, ~180kDa 
Anti-CNR2 monoclonal Antibody [ABGENT #AF1575a] diluted 1:1500 
As described in the Datasheet: 
Host mouse Immunogen: Aminoacids 302-360;  
Detects a Band at 39,7kDa 
 
Loading control 
Anti-GAPDH monoclonal Antibody [CALBIOCHEM #CB1001] diluted 1:8000 
As described in the Datasheet: 
Host mouse;  
Detects Band at ~36kDa for monomeric unit 
 
Membranes were incubated for 16hours at 4°C with the primary antibody. Then they were 
washed 3x for 5minutes with PBS + 0,1% Tween20. Subsequently, they were incubated 
45minutes at RT in the dark with the secondary antibody. 
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Both secondary antibodies were diluted 1:17 5000 
IRDye 680 Conjugated Goat Polyclonal Anti-Mouse IgG (H+L) [LI-COR #926-32220] 
Used for anti-CNR2 and GAPDH primary antibody 
IRDye 800CW Conjugated Goat Polyclonal Anti-Rabbit IgG (H+L) [LI-COR # 926-32211] 
Used for anti-CNR1 antibody 
 
The washing step was repeated and finally the membranes were rinsed with PBS and stored 
in PBS at 4°C. 
 
3.10. Detection 
 
For Detection of proteins on the membrane, the Odyssey Imager was used. This is a Near-
infrared (NIR) fluorescence detection system detecting the fluorescence of the labelled 
secondary antibodies.  
 
3.11. Viability Assays 
 
Viability assays were performed by CellTiter-Blue® Cell Viability Assay. This is a fluorometric 
assay, in which the metabolic capacity of cells to reduce resazurin into fluorescent resorufin 
is measured. At first, cell number and incubation time with the CellTiter Blue reagent were 
adopted to each cell line and to primary cells following the manual. The viability assay was 
performed in triplicates in 96 well plates and at a volume of 100µl. Twenty µl of CellTiter Blue 
reagent was added and the plates were incubated at 37°C under standard conditions. 
Fluorescence was detected using TriStar at an excitation wave length of 570nm and an 
emission wave length of 600nm. Results were transferred to Excel 2003 and viability was 
calculated with medium=blank; and cells plus vehicle set as 100% viability. For creating 
graphs and calculating IC50 values the software GraphPad Prism5 was used. 
 
3.11.1. Cell lines 
 
Cells were transferred to a 50ml Falcon, centrifuged at 1200rpm for 10minutes at RT. Pellets 
were resuspended in RPMI1640 without phenol red, DMEM without phenol red was used for 
A-549. Cells were counted. All cell lines were tested at a density of 25x104 cells/ml, except  
A-549 which were tested at 10x104 cells/ml. Adherent cell lines, M2-10B4 and A-549, were 
seeded directly in 96 flat bottom well plates at a concentration of 25x104 cells/ml or 10x104 
cells/ml and incubated 24h under standard conditions before compound or vehicle was 
added to the well. For cells in suspension culture (MEC-1, MEC-2, JURKAT), aliquots of 
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400µl were prepared in reaction tubes.Then, compounds or vehicle (1%) were added to the 
reaction tubes, using concentrations of 5 – 100µM. Tubes were shortly vortexed and 100µl in 
triplicates were transferred into 96 well plates.  
Cells were incubated 24h and 48h with the compounds. Incubation time after 20µl 
CellTiterBlue reagent was added were 3h for MEC-1, MEC-2, A-549, and M2-10B4, and 4h 
for JURKAT cells. For each cell line the assay was done twice in triplicates. 
 
3.11.2. CLL and healthy donors’ primary cells 
 
CLL cells were tested both in suspension and in coculture. Primary cells from three healthy 
donors were tested only in suspension culture. 
 
Suspension culture 
Experiments were carried out using 3x106 cells/ml in 96 well plates. Preparation was done as 
described for cell lines. Pre-diluted compounds were added, tubes were vortexed and 100µl 
were pipetted in 96well plates in triplicates. Plates were incubated 48h under standard 
conditions. CellTiter Blue reagent was added (20µl) and plates were incubated for 3h. 
 
Coculture 
For coculture experiments, 2x105 M210B4 cells per 630µl medium were seeded in 12 well 
plates and incubated 24h under standard conditions. On the next day, 3x106 CLL primary 
cells in 370µl medium were transferred to the wells (concentration 3x106cell / ml). Finally the 
compounds were added and plates were incubated 48h under standard conditions. To 
determine viability, 100µl of CLL cells were removed from the 12 well plates and pipetted into 
96 wells plates in triplicates. Next, 20µl of CellTiterBlue reagent was added and plates were 
incubated 3h. 
 
3.11.3. Tested Cannabinoids 
 
See 2.1. Cannabinoids used in this study 
R-(+)-Methanandamide in EtOH as vehicle 
ACEA in EtOh as vehicle 
JWH133 in DMSO as vehicle 
(-)-Cannabidiol in DMSO as vehicle 
AM251 in DMSO as vehicle 
AM630 in DMSO as vehicle 
Vehicles in wells did not exceed 1%. 
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3.11.4. Microenvironmental model for drug treatment model 
 
AMD3100 is an established CXCR4 antagonist. Aim was to test whether interfering with the 
CXCR4/CXCL12 axis makes CLL cells more susceptible to the chemotherapeutic 
fludarabine. 
Furthermore, it was tested whether CNR1 and CNR2 agonists and antagonist exert an 
additive effect with fludarabine and to compare the impact of cannabinoids with AMD3100.  
As described in 3.11.2. coculture, M2-10B4 were seeded 24h before the experiment in12 
well plates. Primary PBMC from a CLL patient were thawed and cultured for 24h at 37°C as 
previously described. Since the primary cells of a patient are limited, for the agonist and 
antagonist incubation only samples from two different patients were used. 
As a blank two wells were filled up to 1ml volume and 10µl DMSO or Ethanol were added as 
vehicle. In the other wells 3x106 CLL cells/ml were added. 
In the first well with M2-10B4/CLL coculture 5µM fludarabine was added. In the second well 
0,629mM AMD3100 was pipetted and in a third well, cells were pre-treated 30minutes with 
0,629mM AMD3100 and then 5µM fludarabine was added. 
To test the effect of cannabinoids alone, three wells were incubated with JWH133 with 
different concentrations (10µM, 20µM, 40µM). To the next three wells ACEA (10µM, 20µM, 
40µM) was added. To evaluate the effect of the antagonist, three wells were incubated with  
(-)-Cannabidiol (10µM), AM251 (30µM) and AM630 (30µM). 
To test the additive effect of cannabinoids with fludarabine additional wells were pre-
incubated 30minutes with JWH133 (10µM, 20µM, 40µM), ACEA (10µM, 20µM, 40µM),   
(-)-Cannabidiol (10µM), AM251 (30µM) and AM630 (30µM). Then 5µM fludarabine was 
added.  
Finally, the plated cells were incubated 48h at 37°C under standard conditions. As control 
3x106 CLL cells/ml were incubated with the vehicle. After incubation 100µl from the 12 well 
plate wells were transferred to a 96 well plate. CellTiterBlue viability assay was performed as 
described before. 
 
3.12. Determining CXCR4 levels in CLL by FACS 
 
Primary cells of a CLL patient were prepared as described in chapter 3.3. One million cells 
each were aliquoted into three FACS tube. Tubes were centrifuged at 2500rpm for 5minutes 
at 4°C. After discarding the supernatant, the pellets were vortexed and 200µl FACS buffer 
was added (FACS buffer = 0,1% BSA in PBS). The centrifugation step was repeated and 
50µl FACS buffer were added to the pellets. The first FACS tube was used as a negative 
control, without staining. 
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The second FACS tube was used for CXCR4 staining. For this, 2,5µl of Mouse Anti-Human 
CD184 (CXCR4)-PE [BD Pharmigen #555974] were added and incubated for 20minutes in 
the dark. The third FACS tube was stained for isotype control using 2,5µl of Mouse IgG2a κ 
Isotype Ctrl [BioLegend # 401501] and incubated for 20minutes in the dark. 
Next, 800µl FACS buffer were added to each tube, cells were centrifuged at 2500rpm 
5minutes at 4°C, supernatant was discarded and pellets vortexed. Two hundred µl of FACS 
buffer were transferred to the negative control and the CXCR4 stained sample. Fifty µl FACS 
buffer were added to the isotype control for secondary antibody staining. The secondary 
antibody, goat anti-mouse IgG-Alexa Fluor488 [Invitrogen # A11001], was diluted 1:400 in 
PBS and 1µl was added to the FACS tube. After 20minutes of incubation in the dark, cells 
were washed as described previously. Finally 200µl FACS buffer were transferred into the 
tube and cells were resuspended. The FACS analysis was performed using FACScan 
[Becton Dickinson] and the software CellQuest Pro.  
 
3.13. Migration assays 
 
Migration assays were performed in 6,5mm diameter, 5,0µm pore size polycarbonate 
membrane transwell inserts in 24 well plate after pre-incubation with compounds.  
Two migration assays were done with pre-incubation settings. 
For pre-incubation primary cells of five CLL patients were cultured as described in chapter 
3.3. and seeded into 10 wells of a 12 well plate with 5x106 cells/ml. Compounds were added 
into the wells 1-10 followed by incubation at 37°C.  
 
Pre-incubation settings were as follows 
  1. Control well (no compound added) 
  2. 0,629mM AMD3100 0,5h incubation 
  3. 10µM ACEA 1h incubation 
  4. 0,1µM AM251 0,5h incubation followed by 10µM ACEA for 1h 
  5. 0,1µM AM251 0,5h incubation 
  6. 10µM JWH133 1h incubation 
  7. 0,1µM AM630 0,5h incubation followed by 10µM JWH133 for 1h 
   8. 0,1µM AM630 0,5h incubation 
   9. 0,1% DMSO 1h incubation 
10. 0,1% EtOH 1h incubation 
3. Methods 
24 
For migration, 600µl RPMI1640 without phenol red were pipetted into the bottom wells of the 
24 well plates. CXCL12 (0,1µg/ml) or vehicle control (0,1% PBS with 0,1% BSA) was added 
to the medium. Then transwell inserts were added to the wells. 
Next, 100µl pre-incubated cells were transferred to the inserts. Migration was allowed to 
occur for 4h at 37°C. Then, the contents of the transwell inserts and the bottom wells were 
transferred to separate reaction tubes. Tubes were centrifuged for 5minutes at 2500rpm, the 
pellets were resuspended in 200µl PBS, and cells were counted. Migration was calculated 
using the formula: 
Cells in transwell + cells in bottom well = 100% of cells 
Cells in bottom well = % of cells migrated  
 
3.14. Statistical methods 
 
CNR1/2 expressions are given as median, quartiles and range. The median was set as a cut-
off level for CNR expression to determine CNR high and low expression groups. The impact 
of CNR mRNA expression on survival was illustrated by Kaplan-Meier plots. Progression free 
survival was calculated from first treatment to progression, overall survival was measured 
from date of first diagnosis to follow up and treatment free survival was calculated from date 
of first diagnose till first treatment or follow up. Prognostic markers were compared between 
groups using Chi2-tests. As test for the independence of the prognostic marker a 
coxregression was performed. P-values were calculated by Logrank test. P-values ≤ 0,05 
were considered statistical significant. All computations were performed using SPSS version 
20. 
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4. Results 
 
4.1. Patient characteristics 
 
Table 1 lists clinical characteristics of the patients included in the study. Of the 108 CLL 
patients, 102 CLL patients were used for the mRNA expression studies. 
The median age at diagnosis was 62 years (range 25-85). There were slightly more male 
(59,8%) than female patients (40,2%). 83,8% of the patients had Binet stage A with a 
lymphoid doubling time <1 year in 23,7% of patients. The mutations status of the IGHV 
genes was unmutated in 45,6% of patients. The median expression for CD38 was 10% 
(range 0-91). Chromosomal aberrations were found in 74% of the patients.  
 
Table 1: Clinical characteristics at diagnosis for CLL patients included in this study (N=102). 
N: Number of patients; Del: Deletion; Tris: Trisomy; Rearr: Rearrangement. 
 
Age at diagnosis (N=100) [years] 
Median (Range) 62 (25–85) 
Sex Female : Male (N=102) [%] 40,2 : 59,8 
Binet at diagnosis (N=99) [%] 
A 
B 
C 
 
83,8 
12,1 
4,0 
Mutational status (N=90) [%] 
Unmutated 
Mutated 
 
45,6 
54,4 
Lymphocyte doubling time (N=93) [%] 
High < 1year 
Low > 1year 
 
23,7 
76,3 
CD38 (N=93) [%] 
Low < 30 
High > 30 
Median (Range) 
 
67,7 
32,3 
10 (0-91) 
Del13q (N= 96) [%] 
Unmutated<5,0 
Mutated>5,0 
 
47,9 
52,1 
Tris12 (N=96) [%] 
Unmutated<3,7 
Mutated>3,7 
 
88,5 
11,5 
Del11q (N=96) [%] 
Unmutated<8,6 
Mutated>8,6 
 
76,0 
24,0 
p53 (N=96) [%] 
Unmutated<10,2 
Mutated>10,2 
 
91,7 
8,3 
Rearr14q (N=96) [%] 
Unmutated<3,0 
Mutated>3,0 
 
88,5 
11,5 
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4.2. CNR1 mRNA expression 
 
Median mRNA expression for CNR1 was 1,34 (range 0,00-140,39) in our cohort (Fig. 1A). 
Expression was normalized to four CD19 sorted healthy donor PBMCs. Using the median as 
a cut-off, patients were categorized into high and low expression groups (Fig. 1B). Median for 
low expression group was 0,20 (range 0,00-1,12) and for high expression group 5,94   
(range 1,34-140,39) (Fig. 1B). 
 
 
Figure 1: CNR1 mRNA expression in a cohort of 102 CLL patients.  
A: Box plot CNR1 expression. 
B: Box plot of CNR1 low/high expression groups (N=50 vs. 52). 
Note logarithmic scale on y-axis. 
 
After the CLL patients were categorized into high and low CNR1 expressing subgroups, 
prognostic markers were compared between the two groups. As Table 2 shows, almost 
equal numbers of patients fell into the CNR1 high and the CNR1 low expression group, 
respectively.  
To test for correlation between expression and established prognostic markers a Chi2-test 
was done. 
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Table 2: Patient characteristics for CNR1 high (N=52) and CNR1 low (N=50) expressing 
subgroups. 
N: Number of patients; Del: Deletion; Tris: Trisomie; Rearr: Rearrangement. 
P-values ≤ 0,05 significant. 
CNR1 low CNR1 low CNR1 high 
CNR1 
high 
p-
value 
Age at diagnosis (N=48) 
[years] 
Median (Range) 
59  
(25-85) 
Age at diagnosis (N=52) 
[years] 
Median (Range) 
63  
(39-82) 
 
Sex Female : Male (N=50) 
[%] 44 : 56 
Sex Female : Male (N=52) 
[%] 36,5 : 63,5  
Binet at diagnosis (N=47) 
[%] 
A 
B/C 
 
91,5 
8,5 
Binet at diagnosis (N=52) 
[%] 
A 
B/C 
 
76,9 
23,1 
0,049 
Mutational status (N=45) [%] 
Unmutated 
Mutated 
 
31,1 
68,9 
Mutational status (N=45) [%] 
Unmutated 
Mutated 
 
60,0 
40,0 
0,006 
Lymphocyte doubling time 
(N=46) [%] 
High < 1year 
Low > 1year 
 
15,2 
84,8 
Lymphocyte doubling time 
(N=47) 
High < 1year 
Low > 1year 
 
31,9 
68,1 
0,058 
CD38 (N=46) [%] 
Low < 30 
High > 30 
Median (range) 
 
78,3 
21,7 
4 (0-91) 
CD38 (N=47) [%] 
Low < 30 
High > 30 
Median (range) 
 
57,4 
42,6 
24 (0-89) 
0,032 
Del13q (N= 45) [%] 
Unmutated<5,0 
Mutated>5,0 
 
44,4 
55,6 
Del13q (N=51) [%] 
Unmutated<5,0 
Mutated>5,0 
 
51,0 
49,0 
0,522 
Tris12 (N=45) [%] 
Unmutated<3,7 
Mutated>3,7 
 
88,9 
11,1 
Tris12 (N=51) [%] 
Unmutated<3,7 
Mutated>3,7 
 
88,2 
11,8 
0,920 
Del11q (N=45) [%] 
Unmutated<8,6 
Mutated>8,6 
 
82,2 
17,8 
Del11q (N=51) [%] 
Unmutated<8,6 
Mutated>8,6 
 
70,6 
29,4 
0,183 
p53 (N=45) [%] 
Unmutated<10,2 
Mutated>10,2 
 
88,9 
11,1 
p53 (N=51) [%] 
Unmutated<10,2 
Mutated>10,2 
 
94,1 
5,9 
0,355 
Rearr14q (N=45) [%] 
Unmutated<3,0 
Mutated>3,0 
 
93,3 
6,7 
Rearr14q (N=51) [%] 
Unmutated<3,0 
Mutated>3,0 
 
84,3 
15,7 
0,166 
 
 
A clear association between CNR1 expression and advanced clinical stage could be 
observed, CNR1 high expressing patients more often were diagnosed with Binet stages B 
and C compared to low expressing patients (p=0,049). Similarly, CNR1 high expressing 
patients were more likely to have unmutated IGVH genes (60% vs. 31,1%, p=0,006) and high 
CD38 expression (42,6% vs 21,7%, p=0,032). 
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Lymphocyte doubling time (LDT) was high in 15,2% of patients within the CNR1 low 
expressing and in 31,9% within the high expressing group. With a p-value of 0,058 this could 
indicate a trend for an association between LDT and CNR1 mRNA expression.  
The prevalence of cytogenetic aberrations (Del13q, Tris12, Del11q, p53, Rearr14q) did not 
differ significantly between the groups. 
 
4.3. Survival analysis for CNR1 mRNA expression 
 
In order to determine whether CNR1 expression levels correlate with survival, a Kaplan-
meier survival analysis with N=100 patients was calculated (Fig. 2).  
 
 
Figure 2: Overall survival for CNR1 high (N=52) and low expressing CLL patients (N=48). 
 
Low CNR1 expression was indicative for longer overall survival (mean 277 months vs. 155 
months, p=0,002). The low expression group showed 90% survival after 200 monthswhereas
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the high expression cohort had a survival of 50%. The logrank test revealed a significant 
difference between the two cohorts (p-value=0,002).  
 
 
Figure 3: Treatment free survival for CNR1 high (N=52) and low (N=47) expressing CLL 
patients. 
 
In addition to overall survival (OS), a significant difference were also observed for treatment 
free survival (TFS) in N=99 patients (p=0,000) (Fig. 3). Mean TFS was 152 months in the low 
expression group, compared to 70 months in the high expression group. A multivariat 
analysis revealed that the influence on OS and TFS is independent from CD38 expression, 
Binet stage and LDT, but depends on IGHV mutation status.  
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Figure 4: Progression free survival for CNR1 high (N=36) and low (N=19) expressing CLL 
patients. 
 
In contrast to OS and TFS, progression free survival between the CNR1 high and low 
expressing groups was not significantly different (N=55) (Mean 34 months low expression 
group vs. 32 month high expression group; p=0,106) (Fig. 4).  
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4.4. Protein expression of CNR1 
 
To investigate whether protein levels follow the mRNA expression levels, Westernblots with 
high CNR1 mRNA expression CLL patients (N=10) (Fig. 5A+B) and with low CNR1 mRNA 
expression patients (N=10) were done (Fig. 6A+B). The relative fold increase in mRNA 
expression for CNR1 is listed in the table below the picture. To account for the case that the 
CNR1 antibody might bind unspecific to CNR2, CNR2 mRNA expression also was included. 
 
 
Figure 5: CNR1 protein expression in CNR1 mRNA high expressing CLL patients (N=10). 
As positive controls, the cell lines A-549 and JURKAT and recombinant CNR1 and CNR2 proteins 
were used. Sixty µg of the samples, 0,19 µg of recombinant CNR1 and 0,1µg of recombinant CNR2 
were loaded into the slots. As protein marker 2µl of peqGOLD Protein-Marker IV was used. The IRDye 
800CW [LI-COR] as secondary antibody for CNR1 was detected in the 800nm channel of the 
Odyssey, the IRDye 680 labelled secondary antibody for GAPDH was detected in the 700nm channel. 
A + B: Westernblost with 5 different CLL patients each. 
 
The calculated size for CNR1 is around 53kDa and the CNR1 antibody is described to show 
bands at ~60kDa and lighter bands at ~23kDa, ~72kDa, ~180kDa. In the recombinant protein 
control, the antibody detected a band at the described 53kDa for the CNR1 protein plus 
bands under 34kDa and bands at 130kDa and 170kDa (Fig. 5A+B). Since there were no 
bands detected for the CNR2 recombinant protein, the antibody seemed to be specific for 
CNR1. However, the CNR1 antibody detected bands in JURKAT cells, which do not express 
CNR1 mRNA. All CLL patients and the cell lines showed bands at the same size (34kDa, 
72kDa) and additional at 52kDa for the A-549.  
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The same results were obtained, when patients with a low mRNA expression were screened 
for protein expression (Fig. 6A+B).  
 
 
 
Figure 6: CNR1 protein expression in CNR1 mRNA low expressing CLL patients (N=10).  
As positive controls, the cell lines A-549 and JURKAT and recombinant CNR1 and CNR2 proteins 
were used. Sixty µg of the samples, and 0,19 µg of recombinant CNR1 and 0,1µg of recombinant 
CNR2 were loaded into the slots. As protein marker 2µl of peqGOLD Protein-Marker IV was used. The 
IRDye 800CW [LI-COR] as secondary antibody for CNR1 was detected in the 800nm channel of 
Odyssey, the IRDye 680 as secondary antibody for GAPDH was detected in the 700nm channel. 
A + B: Westernblost with 5 different CLL patients each. 
 
Comparing the high and low CNR1 expressing patients (Fig. 5+6), no association between 
mRNA expression level and protein expression could be observed. In addition, no 
association between CNR1 protein expression with CNR2 mRNA high or low expression 
levels could be detected in the westernblots. As a control, the GAPDH loading control 
revealed that the amounts of protein loaded within one westernblot were similar.  
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4.5. CNR2 mRNA expression 
 
As for CNR1, CNR2 mRNA expression levels were determined for the 102 CLL patients (Fig. 
7A). Median CNR2 mRNA expression was 3,60 ranging from 0,06 to 14,37. The median of 
3,60 was used as a cut-off and the cohort was split into CNR2 high and low expression 
groups (Fig. 7B). The median for the low expression group was 2,28 (range 0,06-3,59) 
compared to 5,12 (range 3,61-14,37) of the high expressing groups (Fig. 7B). 
 
 
Figure 7: CNR2 mRNA expression in a cohort of 102 CLL patients.  
A: Box plot CNR2 expression. 
B: Box plot of CNR2 low/high expression groups (N=51 vs. 51). 
Note logarithmic scale on y-axis. 
 
Also for CNR2, patient characteristics were analyzed for high (N=51) and low (N=51) 
expression groups separately and then compared.  
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Table 3: Patient characteristics for CNR2 high (N=51) and low (N=51) expressing subgroups. 
N=number of patients, Del: Deletion; Tris: Trisomie; Rearr: Rearrangement. 
P-values ≤ 0,05 significant. 
CNR2 low CNR2 low CNR2 high CNR2 high 
p-
value 
Age at diagnosis 
(N=50) [years] 
Median (Range) 
65  
(39-85) 
Age at diagnosis 
(N=50) 
Median (Range) 
60  
(25-80) 
 
Sex Female :Male 
(N=51) [%] 45,1 : 54,9 
Sex Female :Male 
(N=51) [%] 35,3 : 64,7  
Binet at diagnosis 
(N=49) 
A 
B/C 
 
85,7 
14,3 
Binet at diagnosis 
(N=50) 
A 
B/C 
82,0 
18,0 
0,616 
Mutational status 
(N=45) [%] 
Unmutated 
Mutated 
46,7 
53,3 
Mutational status 
(N=45) [%] 
Unmutated 
Mutated 
44,4 
55,6 
0,832 
Lymphocyte doubling 
time (N=47) 
High < 1year 
Low > 1year 
25,5 
74,5 
Lymphocyte doubling 
time (N=46) 
High < 1year 
Low > 1year 
21,7 
78,3 
0,667 
CD38 (N=48) [%] 
Low < 30 
High > 30 
Median (range) 
68,8 
31,3 
7,5 (0-85) 
CD38 (N=45) [%] 
Low < 30 
High > 30 
Median (range) 
66,7 
33,3 
17 (0-91) 
0,830 
Del13q (N= 46) [%] 
Unmutated<5,0 
Mutated>5,0 
 
54,3 
45,7 
Del13q (N=50) [%] 
Unmutated<5,0 
Mutated>5,0 
42,0 
58,0 
0,226 
Tris12 (N=46) [%] 
Unmutated<3,7 
Mutated>3,7 
 
91,3 
8,7 
Tris12 (N=50) [%] 
Unmutated<3,7 
Mutated>3,7 
86,0 
14,0 
0,415 
Del11q (N=46) [%] 
Unmutated<8,6 
Mutated>8,6 
80,4 
19,6 
Del11q (N=50) [%] 
Unmutated<8,6 
Mutated>8,6 
 
72,0 
28,0 
0,333 
p53 (N=46) [%] 
Unmutated<10,2 
Mutated>10,2 
 
93,5 
6,5 
p53 (N=50) [%] 
Unmutated<10,2 
Mutated>10,2 
 
90,0 
10,0 
0,538 
Rearr14q (N=46) [%] 
Unmutated<3,0 
Mutated>3,0 
84,8 
15,2 
Rearr14q (N=50) [%] 
Unmutated<3,0 
Mutated>3,0 
 
92,0 
8,0 
0,267 
 
 
In contrast to CNR1, no significant association between any of the established prognostic 
markers, clinical stage, unmutated IGHV genes, LTD, CD38 expression, or cytogenetic 
aberrations, and CNR2 mRNA expression could be observed (Table 3). 
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4.6. Survival analysis for CNR2 expression 
 
Again, Kaplan-Meier survival curves were calculated for overall survival for CNR2 high and 
low expressing groups (N=100) (Fig. 8). Mean OS for high expressing patients was 206 
months vs. 234 months for low expressing patients (p=0,738). Thus, CNR2 expression is not 
significantly associated with overall survival in CLL.  
 
 
 
Figure 8: Overall survival for CNR2 high (N=50) and low expressing CLL patients (N=50). 
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Figure 9: Treatment free survival for CNR2 high (N=50) and low (N=49) expressing CLL 
patients. 
 
Neither is mRNA expression of CNR2 associated with longer treatment free survival (N=99) 
(p=0,120) (Fig. 9). Mean for low expression 136 months vs. 95 months for high expression.
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Figure 10: Progression free survival for CNR2 high (N=35) and low expressing CLL patients 
(N=20). 
 
Likewise, no significant association could be observed for CNR2 mRNA expression levels 
and progression free survival (N=55) (Fig. 10), underlining that mRNA expression of this 
gene appears not to have an impact on survival of CLL patients (mean 22 month low 
expression group vs. 31 month for high expression; p value=0,133). 
 
4.7. Protein expression of CNR2 
 
As for the CNR1, CLL patients with high (N=10) (Fig. 11A+B) and low CNR2 mRNA 
expression (N=10) (Fig. 12A+B) were tested in Westernblots to see whether protein levels 
follow the mRNA expression levels. Beside the mRNA expression of CNR2, the CNR1 
mRNA levels are also shown in the tables, in case the antibody detects not exclusively the 
CNR2 protein.  
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Figure 11: CNR2 protein expression in CNR2 mRNA high expressing CLL patients (N=10).  
As positive controls, the cell lines A-549 and JURKAT and recombinant CNR1 and CNR2 proteins 
were used. Sixty µg of the samples, 0,19 µg of recombinant CNR1 and 0,1µg of recombinant CNR2 
were loaded into the slots. As protein marker 2µl of peqGOLD Protein-Marker IV was used.  
IRDye 680CW [LI-COR] as secondary antibody for CNR2 and GAPDH was detected in the 700nm 
channel. 
A + B: Westernblost with 5 different CLL patients each.  
 
The predicted size for CNR2 is ~40kDa and the antibody is described to detect a band at 
39,7kDa. The recombinant protein controls revealed that the antibody detected specific 
CNR2, since no bands were shown for the recombinant CNR1 (Fig. 11A+B). Beside the 
specific band at ~40kDa, additional bands at ~72kDa and ~130kDa were seen. Between cell 
lines and CLL patients, no difference in band size was seen. Even the A-549 cell line, which 
does not express CNR2 mRNA had the same band pattern as JURKAT cells (Fig. 11A+B). 
As for recombinant CNR2, the monoclonal antibody did not only detect bands at the 
predicted size (~40kDa) in CLL cells and cell lines, additional bands at higher size were also 
detected. 
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Figure 12: CNR2 protein expression in CNR2 mRNA low expressing CLL patients (N=10). 
As positive controls, the cell lines A-549 and JURKAT and recombinant CNR1 and CNR2 proteins 
were used. Sixty µg of the samples, 0,19 µg of recombinant CNR1 and 0,1µg of recombinant CNR2 
were loaded into the slots. As protein marker 2µl of peqGOLD Protein-Marker IV was used. IRDye 
680CW [LI-COR] as secondary antibody for CNR2 and GAPDH was detected in the 700nm channel. 
A + B: Westernblost with 5 different CLL patients each.  
 
Comparing the high expression cohort with the CNR2 low expression cohort, no difference in 
band size and pattern were seen (Fig. 11A+B + Fig. 12A+B). The GAPDH control revealed 
for each westernblot an equal protein load (Fig. 11A+B + Fig. 12A+B). It was not possible to 
evaluate the difference in protein level as seen in the mRNA level.  
 
4.8. Impact of cannabinoids on viability of cell lines 
 
To evaluate the responsiveness of malignant cells to cannabinoids, viability assays were 
performed. Cell lines were incubated for 24h and 48h with selected compounds, decrease of 
viability was measured, and IC50 values were determined. In addition, CNR mRNA 
expression was determined for the four cell lines used (MEC-1, MEC-2, JURKAT and A-549) 
whether induction of cell death might correlate with gene expression.  
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Figure 13: Viability of cell lines incubated with (R)-(+)-Methanadamide for 24 and 48h.  
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
Figure 13 shows changes in viability for the four cell lines upon incubation with different 
concentrations of (R)-(+)-Methanandamide, the stable analog of the endocannabinoid 
anandamide and agonist of CNR1. For all four cell lines, a time and concentration dependent 
decrease in viability could be observed (Fig. 13A-D). In particular, A-549 was resistant to 
treatment with an extrapolated IC50 103,84µM after 24h and 96,74µM after 48h of incubation 
(Fig. 13D). 
Levels of mRNA expression of CNR1 and CNR2 are listed in Figure 13E. As reported in the 
literature, JURKAT cells were positive only for CNR2 mRNA expression and A-549 only for 
mRNA expression of CNR1. The cell lines MEC-1 and MEC-2 were positive for both 
receptors (relative to A-549 and JURKAT) although to a varying degree. Despite different 
CNR1 mRNA expression levels, MEC-1, MEC-2 and JURKAT show similar sensitivities 
toward the CNR1 agonist (R)-(+)-Methanandamide.  
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Figure 14: Viability of cell lines incubated with (-)-Cannabidiol for 24 and 48h. 
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
Next, the four cell lines were tested for (-)-Cannabidiol, a non-psychotropic constituent of 
cannabis acting on both cannabinoid receptors. As for (R)-(+)-Methanandamide a dose 
dependent cytotoxic effect, but not a time dependent one, could be observed. The IC50 
values were, generally, 3-4 fold lower than for (R)-(+)-Methanandamide (Fig. 14). All four cell 
lines showed similar IC50 values, although they express the CNRs to different extents (Fig. 
14E). 
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Figure 15: Viability of cell lines incubated with ACEA for 24 and 48h.  
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
The following set of experiments was carried out using one selective agonist and antagonist 
for each receptor, respectively.  
In figure 15, the cell lines were incubated with the selective CNR1 agonist ACEA. Whereas 
MEC-2 and JURKAT showed only a concentration dependent drop in viability, MEC-1 had a 
concentration and time dependent decrease (Fig. 15A-C). On the A-549 cells, ACEA had the 
greatest impact on viability after 48h incubation (IC50 = 9,74µM), but it had no effect in the 
24h incubation assay (Fig. 15D). No association between the sensitivity toward the CNR1 
agonist and the CNR1 mRNA expression level could be observed.  
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Figure 16: Viability of cell lines incubated with JWH133 for 24 and 48h.  
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
In the next experiment, cells were incubated with the CNR2 agonist JWH133 (Fig. 16). All 
four cell lines showed a time and concentration dependent decrease in viability. In the case 
of MEC-2 and A-549, the IC50 value was not reached in the 24h incubation setting (Fig. 
16B+D). Comparing the different cell lines, JURKAT cells were more sensitive than the other 
cell lines (Fig. 16C). They also express the highest level of CNR2 mRNA (Fig. 16E). Still, for 
the other cells there was no association between mRNA expression levels and viability 
detected. 
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Figure 17: Viability of cell lines incubated with AM251 for 24 and 48h.  
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
Incubation with the CNR1 antagonist AM251 led to a time and dose dependent decrease in 
viability for MEC-1, MEC-2 and JURKAT (Fig. 17A-C). The A-549 cells showed some 
resistance, the IC50 value could not be reached in 24h and 48h incubation (Fig. 17D). The 
mRNA expression was not associated with viability.  
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Figure 18: Viability of cell lines incubated with AM630 for 24 and 48h.  
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for MEC-1. 
B: Viability and IC50 values for MEC-2. 
C: Viability and IC50 values for JURKAT. 
D: Viability and IC50 values for A-549. 
E: mRNA expression of CNR1 and CNR2 for the cell lines. 
 
The cell lines were then incubated with AM630, a CNR2 antagonist (Fig. 18). The IC50 was 
not reached for the A-549, which do not express CNR2 mRNA, in 24h and 48h incubation 
(Fig. 18D). The JURKAT cell line, with the highest CNR2 mRNA expression, showed the 
highest sensitivity toward AM630 in the 48h incubation setting (IC50 = 9,71µM), whereas the 
IC50 value was not reached in 24h incubation (Fig. 18C). MEC-1 and MEC-2 showed a time 
and concentration dependent drop in viability, where the MEC-2 were slightly more 
susceptible. MEC-2 cells have higher CNR2 mRNA expression than MEC-1. Therefore, at 
least for the AM630 an association between the mRNA level and sensitivity needs to be 
taken into consideration.  
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Figure 19: Viability of M2-10B4 incubated with different compounds for 24 and 48h. 
Viability was calculated relative to vehicle control. 
A: Viability and IC50 values for M2-10B4 incubated with (R)-(+)-Methanandamide. 
B: Viability and IC50 values for M2-10B4 incubated with (-)-Cannabidiol. 
C: Viability and IC50 values for M2-10B4 incubated with JWH133. 
D: Viability and IC50 values for M2-10B4 incubated with ACEA. 
E: Viability and IC50 values for M2-10B4 incubated with AM251. 
F: Viability and IC50 values for M2-10B4 incubated with AM630. 
Note different scales on X-axis. 
 
Finally, viability screens were also carried out with the mouse fibroblast cell line M2-10B4. 
Since these cells would be used as feeder cells in coculture assays with CLL primary cells, it 
was important to determine the extent of cannabinoid induced cytotoxicity in the cells. These 
cells exert resistance toward JWH133, ACEA and AM251 incubation (Fig. 19C-E). For the 
incubation with AM630, (R)-(+)-Methanandamide and (-)-Cannabidiol they showed a time 
and concentration dependent drop in viability (Fig. 19A+B+F). (-)-Cannabidiol had the 
strongest impact on viability (Fig. 19B).  
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4.9. Impact of cannabinoids on viability of primary cells 
 
After testing the CNR1 and CNR2 agonists and antagonists on cell lines, primary cells from 
CLL patients were screened. In contrast to cell lines, primary cells were incubated only for 
48h in suspension culture and with M2-10B4 mouse fibroblasts as feeder layer in coculture 
(Fig. 20).  
 
 
Figure 20: Impact of cannabinoids on primary cells from CLL patients. 
Cells were incubated with different concentrations of compounds in suspension culture and coculture 
for 48h. Viability was calculated relative to vehicle control. 
A: CLL primary cells incubated with R-(+)-Methanandamide (N=10). 
B: CLL primary cells incubated with (-)-Cannabidiol (N=18). 
C: CLL primary cells incubated with ACEA (N=16). 
D:  CLL primary cells incubated with JWH133 (N=16). 
E: CLL primary cells incubated with AM251 (N=16).  
F: CLL primary cells incubated with AM630 (N=16). 
Note different scales on X-axis. 
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In the coculture incubation setting, CLL cells were less sensitive toward the cannabinoids 
and the IC50 value could not be calculated in coculture during incubation with ACEA, 
JWH133 and AM251. The IC50 value was slightly higher in coculture compared to 
suspension culture for (R)-(+)-Methandamide incubation (Fig. 20A+C+D+E). Incubations with 
(-)-Cannabidiol and AM630 were exceptions for the observed resistance in coculture (Fig. 
20B+F). Their IC50 values in coculture were similar to the sensitivity of the M2-10B4 after 
48h incubation. Comparing the IC50 for suspension culture, JWH133 the CNR2 agonist had 
the lowest impact on the cells (75,68µM) and the CNR1 antagonist AM251 the strongest 
(9,43µM) (Fig. 20D+E). 
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Figure 21: Impact of cannabinoids on primary cells from healthy donors (HD). 
Cells were incubated with different concentrations of compounds in suspension culture for 48h. 
Viability was calculated relative to vehicle control. 
A: HD primary cells incubated with R-(+)-Methanandamide (N=2). 
B: HD primary cells incubated with (-)-Cannabidiol (N=3). 
C: HD primary cells incubated with ACEA (N=3). 
D: HD primary cells incubated with JWH133 (N=3). 
E: HD primary cells incubated with AM251 (N=3). 
F: HD primary cells incubated with AM630 (N=3). 
Note the different scale of the y-axis for D (JWH133). 
 
In addition to CLL cells, PBMC from healthy donors (HD) were tested to evaluate cytotoxicity 
of the compounds in healthy cells. All cannabinoids led to a dose dependent decrease in 
viability (Fig. 21). The sensitivity and therefore the IC50 values differed between compounds. 
Thus, incubation with AM251 and (-)-Cannabidiol had the strongest impact on the cells, 
whereas JWH133 and R-(+)-Methanandamide exerted only moderate cytotoxicity with high 
IC50 values (Fig. 21). For better comparison of the effects of cannabinoids on the different 
cells used, the IC50 values after 48h incubation were listed in a table (Table 4).  
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Table 4: Comparison of sensitivity toward cannabinoids. 
IC50 values in µM after 48h incubation. 
NR = IC50 not reached. 
 (R)-(+)-
Methandamide 
(-)-
Cannabidiol 
ACEA JWH133 AM251 AM630 
MEC-1 50,76 14,52 19,41 57,31 17,04 22,58 
MEC-2 48,15 16,01 34,86 57,53 13,86 19,56 
JURKAT 44,91 14,27 33,45 43,45 15,78 9,71 
A-549 96,74 11,36 9,74 52,79 NR NR 
CLL 
suspension 
33,19 21,74 31,78 75,68 9,43 12,08 
CLL 
coculture 
29,27 16,78 NR NR NR 27,64 
M2-10B4 34,55 13,52 NR NR NR 28,27 
HD 60,13 15,09 39,01 78,12 11,44 28,51 
 
Considering the overall cytotoxic effects among the different cell types used, (-)-Cannabidiol 
had the strongest and JWH133 the lowest impact on viability. Among cell lines, A-549 
showed some kind of resistance except for (-)-Cannabidiol and ACEA. The other three cell 
lines MEC-1, MEC-2 and JURKAT were equally affected by the different cannabinoids. 
Comparing the CLL cell lines MEC-1 and MEC-2 with primary CLL cells in suspension, the 
primary cells were similarly susceptible to ACEA, less for JWH133 and  
(-)-Cannabidiol and more affected by AM251, AM630 and (R)-(+)-Methandamide. In 
coculture, the CLL cells were more resistant to the cannabinoids except for (-)-Cannabidiol 
and AM630. For those two compounds, however, as can be seen in table 4, the feeder cells, 
M2-10B4, were affected to an equal extent. Compounds that have a higher influence on the 
cocultured CLL cells than on the primary cells of healthy donors are of interest as potential 
therapeutic drug. But only (R)-(+)-Methandamide was more cytotoxic for CLL cells than for 
the healthy cells (Table 4).  
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To evaluate a potential association between sensitivity to cannabinoids and gene expression, 
IC50 values were plotted versus mRNA expression levels. In some cases, IC50 values could 
not be calculated due to that 50% reduction in viability was not reached, the compound was 
not tested on the CLL sample, or additional data points would have been needed for 
calculation.  
 
 
Figure 22: Decrease in viability in relation to CNR1 mRNA expression levels. 
CLL primary cells were incubated in suspension culture and in coculture with M2-10B4. 
A: CLL primary cells incubates with R-(+)-Methanandamide (N=10). 
B: CLL primary cells incubates with (-)-Cannabidiol (N=18). 
C: CLL primary cells incubates with ACEA (N=16). 
D: CLL primary cells incubates with JWH133 (N=16). 
E: CLL primary cells incubates with AM251 (N=16). 
F: CLL primary cells incubates with AM630 (N=16).  
Note different scales on y-axis. IC50 values could not calculated due to: 
: 50% viability was not reached; ∆: Not tested for the compound; *: Too few data points. 
4. Results 
52 
Figure 22 shows relative CNR1 mRNA expression levels vs. IC50 values for the compounds 
tested. For incubation with (R)-(+)-Methandamide, it can be seen that patients with a high 
CNR1 mRNA expression showed similar IC50 values as patients with low CNR1 mRNA 
expression (Fig. 22A). The same results was shown for the incubation with (-)-Cannabidiol 
(Fig. 22B). Incubation of cells in coculture with ACEA and JWH133 did not induce a reduction 
of viability of > 50% so that IC50 values could not be calculated in most cases. However, 
comparing IC50 values in suspension culture with CNR1 expression levels, no association 
could be observed (Fig. 22C+D). Also for the incubation with the antagonists AM251 and 
AM630 an association between CNR1 expression and sensitivity toward the compounds 
could not be shown (Fig. 22E+F).  
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Figure 23: Decrease in viability in relation to CNR2 mRNA expression levels. 
CLL primary cells were incubated in suspension culture and in coculture with M2-10B4. 
A: CLL primary cells incubates with R-(+)-Methanandamide (N=10). 
B: CLL primary cells incubates with (-)-Cannabidiol (N=18). 
C: CLL primary cells incubates with ACEA (N=16). 
D: CLL primary cells incubates with JWH133 (N=16). 
E: CLL primary cells incubates with AM251 (N=16). 
F: CLL primary cells incubates with AM630 (N=16).  
Note different scales on y-axis. IC50 values could not calculated due to: 
: 50% viability was not reached; ∆: Not tested for the compound; *: Too few data points. 
 
Since there was no clear association between CNR1 mRNA expression and the IC50 values, 
the association between the CNR2 mRNA expression and sensitivity to the compounds was 
also tested (Fig. 23). For (R)-(+)-Methanandamide and (-)-Cannabidiol there was no 
association between the high and low CNR2 expressing samples and the corresponding 
IC50 values (Fig. 23A+B). ACEA and JWH133 showed similar results as for the CNR1 
expression meaning that in coculture IC50 values were mostly not available, since 50% 
reduction of viability was not reached. For incubation in suspension culture, no difference in
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sensitivity in relation to CNR2 expression levels was found (Fig. 23C+D). Finally there was 
no association between the CNR2 expression and viability reduction for incubation with 
AM251 and AM630 (Fig. 23E+F).  
 
4.10. Determining CXCR4 levels in CLL by FACS 
 
The microenvironment plays a critical role in CLL providing survival signals and thus 
contributing to resistance to treatment. Particularly the CXCR4/CXCL12 axis has been 
shown to contribute to survival of leukemic cells. In the literature, CLL cells are described to 
express CXCR4. Therefore, a representative FACS Screen for CXCR4 expression on CLL 
cells was done. 
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Figure 24: Representative FACS analysis for CXCR4. 
Cells were stained for CXCR4 with Mouse Anti-Human CD184 PE, mouse IgG2a κ was used as 
isotype control with Alexa Fluor488-labeled goat anti-mouse as secondary antibody. 
A: Control in FSC and SSC.  
B: Control auto fluorescence.  
C: CXCR4 stained.  
D: Isotype control. 
 
Figure 24 shows one CLL sample analysed with a flow cytometer FACScan. In forward 
scatter (FSC) and sideward scatter (SSC) each dot represents one CLL cell which is located 
on the plot due to its size and granularity. Size was depicted by FSC and granularity by SSC. 
Cells were gated (R1) due to their size and granularity (Fig. 24A). In a next step the threshold 
for auto fluorescence, which was detected by detector FL1 and FL2, was set (Fig. 24B). The 
CXCR4 antibody was PE labelled which was detected in detector FL2. Figure 24C shows 
that 97,78% of the gated cells (red coloured) are located in the lower right and therefore are 
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CXCR4 positive. Therefore the CLL cells tested in the migration assay express the CXCR4. 
An additional isotype control was performed to ensure that the used mouse IgG2a antibody 
used for CXCR4 staining did not bind unspecific to the CLL cells. All cells in the isotype 
control were located in the lower left and are therefore negative (Fig. 24D). They showed no 
signal for Alexa Fluore488 in the FL1 detector. Therefore the CXCR4 detection was specific.  
 
4.11. Microenvironmental model for drug treatment model 
 
Cannabinoids have been implicated in interfering with the CXCL12/CXCR4 axis in T-cells. A 
set of experiments was conducted to explore additive effects of cannabinoids with 
fludarabine, a standard drug in CLL treatment, as has been described for AMD3100, a 
CXCR4 targeting antibody. 
 
 
Figure 25: Interference of cannabinoids with CXCR4/CXCL12 interaction. 
Decrease in viability in CLL primary cells incubated 48h with 5µM fludarabine after 30 minutes pre-
incubation with AMD3100 or CNR1 agonist (ACEA) or CNR2 agonist (JWH133). Mean values and SD 
were calculated from triplicates in 96well plates. 
A: Pre-incubation with CNR1 agonist (ACEA) (N=1). 
B: Pre-incubation with CNR2 agonist (JWH133) (N=1). 
C: Pre-incubation with CNR1 antagonist (AM251) or CNR2 antagonist (AM630), CNR1 antagonist & 
CNR2 inverse agonist ((-)-Cannabidiol) (N=1). 
 
Figure 25 depicts the viability of PBMCs of two CLL patients after 48h incubation in different 
settings. CLL sample incubated with 0,5% DMSO were set as 100% viability. In all settings 
fludarabine reduced viability to 50% (Fig. 25A-C). The strongest impact on viability, even 
more than fludarabine, had the CXCR4 inhibitor, viability was reduced to 9%. This effect was 
not much enhanced when 5µM fludarabine were added for 48h. Incubation with the CNR1 
agonist ACEA at all three concentrations (10µM, 20µM and 40µM) had a similar impact as 
fludarabine alone (33-47% viability) (Fig. 25A). ACEA showed only a minimal additive effect 
to fludarabine (22-25%) when fludarabine was added after ACEA pre-treatment (Fig. 25A).
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A similar result could be seen for the incubation with the CNR2 agonist JWH133. Pre-
incubation with JWH133 resulted in a reduction of viability to ~66%. Viability for the three 
tested concentrations was similar, concerning the high SD (standard deviation) within the 
10µM setting. By adding fludarabine the viability was reduced to 27-37% (Fig. 25B). Thus 
fludarabine and JWH133 had a small additive effect. Finally the same tests were done for the 
CNR1 and CNR2 antagonists. Pre-incubation with 10µM (-)-Cannabidiol, 30µM AM251 or 
30µM AM630 reduced the viability of the CLL cells to 51-61%. The additional incubation with 
fludarabine led only to a slight reduction in viability for the (-)-Cannabidol and AM630 pre-
incubated cells. There was no additional reduction in viability by adding fludarabine, when 
cells were previously incubated with the CNR1 antagonist AM251 (73% viability) (Fig. 25C). 
 
4.12. Impact of cannabinoids on migration of CLL cells towards CXCL12 
 
To further investigate a potential role of cannabinoids in interference with the 
microenvironment, migration assays were performed. Aim was to test whether CLL cells 
expressing the CXCR4 migrate toward the ligand CXCL12 and how incubation with 
cannabinoids alters the migration behaviour. 
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Figure 26: Impact of cannabinoids on migration of CLL primary cells (N=5) towards CXCL12. 
Total cell number of cells in bottom well plus cells in transwell inserts were set as 100%. Percent of 
migrated cells was calculated by dividing the number of cells in the bottom well by the number of total 
cells. The p-values were calculated by Mann-Whitney U test.  
P-value ≤ 0,05 significant. 
 
Figure 26 shows that 16% of untreated primary CLL cells migrated towards CXCL12 
compared to up to 20% in the vehicle controls (DMSO or Ethanol). In the negative control, 
CXCL12 was not added to the bottom well, only 0,1% of cells migrated into the bottom well 
compared to control (p=0,007). When cells were incubated with the CXCR4 inhibitor 
AMD3100, migration was reduced significantly (2,3% migration, p=0,014) compared to 
control. Incubation with the CNR1 agonist ACEA as well as incubation with the CNR2 agonist 
JWH133 led to migration similar to the vehicle treated cells. Incubation with the cannabinoid 
receptor antagonist, AM251 for CNR1 and AM630 for CNR2, respectively, resulted in only 
slightly decreased migration compared to vehicle control. When cells were pre-treated with 
the antagonist before incubation with the corresponding agonist, migration was slightly 
increased, however, not statistically significant to incubation either with agonist or with 
antagonist alone. Thus, and in contrast to AMD3100, the cannabinoids did not exert a 
significant effect on the migration of the primary CLL cells towards CXCL12. 
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5. Discussion 
 
Cannabinoids are the unique active compound of Cannabis sativa L. (Velasco, Sánchez, & 
Guzmán, 2012): Preparations of this plant have been used in medicine for centuries (Velasco 
et al., 2012). Today it is known that cannabinoids exert an anti-proliferative and pro apoptotic 
effect on cancer cells (Guzmán, 2003). In this study, emphasize was put on Chronic 
lymphocytic leukemia (CLL). CLL is the most prevalent leukemia of adults in Western 
countries (Müller-Hermelink et al., 2008). The clinical course is heterogeneous (Malavasi et 
al., 2011), and for the patients, who do not response to treatment and progress rapidly, novel 
therapeutic options are needed. Due to the cytotoxic effects reported for cannabinoids and 
the need for therapeutic drugs in CLL, we wanted to study the cannabinoid receptors and 
their ligands in this malignancy in more detail.  
As first aim of this study, we screened a cohort of CLL patients for the expression of 
cannabinoid receptor 1 (CNR1) and cannabinoid receptor 2 (CNR2).  
As typical for CLL, the percentage of female was slightly lower than that of male (1:1,5), the 
median age was 62 years. In comparison, Müller-Hermelink et al. observed the median age 
for CLL at 65 years with a female:male ratio of 1:1,5-2 (Müller-Hermelink et al., 2008). 
Delago et al. showed in a study dealing with deletion of chromosome 17p a median age of 68 
years in 294 patients (Delgado et al., 2012). 
Literature about CLL reports that about 80% of the CLL cases show cytogenetic 
abnormalities, 50% of the cases have a deletion of chromosome 13q, 20% trisomy of 
chromosome 12 and deletions of chromosome 17, 11 and 6 are found (Müller-Hermelink et 
al., 2008). Similar abundancies of these cytogenetic abnormalities were described by Döhner 
et al. with worse prognosis for deletion of 17 and 11 (Döhner et al., 1999). 
In comparison, in this cohort 74% of the patients showed chromosomal aberrations and 
display similar percentage of deletions and rearrangements as described in the literature.  
Also, 40-50% of patients have unmutated immunoglobulin heavy chain variable region genes 
(IGHV) (Müller-Hermelink et al., 2008). In this cohort 45,6% of the patients showed 
unmutated IGHV genes.  
Thus, our cohort of 102 patients can be considered to be a well representative group of CLL 
patients.  
After normalization of mRNA expression to CD19+ sorted healthy donors, an elevated CNR1 
expression with a high variability within the cohort could be observed. Also CNR2 expression 
was increased compared to healthy donors. In CLL, Gustafson et al. described already an 
enhanced expression of the two receptors compared to control tissue, with only a moderate 
correlation between the expression levels of the two receptors (Gustafsson et al., 2008). 
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Furthermore, comparing the expression medians, a three times higher expression of CNR2 
was observed among CLL patients compared to CNR1.  
Such a 3:1 ratio (CNR2 :CNR1) was also found in PBMCs from healthy groups of different 
age and sex (Nong et al., 2002), and in mantle cell lymphoma (MCL) cells, CNR1 was higher 
expressed than CNR2 (Richardson et al., 2007).  
Since we found an overexpression of the two cannabinoid receptors in CLL, the second aim 
of the study was to evaluate the potential of the cannabinoid receptor mRNA expression 
levels as prognostic makers. Using median expression as cut-off, CLL patients were split into 
CNR high and CNR low expressing cohorts and the data were analyzed accordingly. The 
results revealed that high CNR1 expression was significantly associated with Binet stages B 
+ C. These later stages B and C reflect advanced and/or progressive disease, with more 
involved lymph nodes or organomegaly and anemia/thrombocytopenia (Hallek et al., 2008). 
Furthermore the results showed an association of high CNR1 expression with the IGHV 
mutational status, the CNR1 high expression group showed a higher percentage of 
unmutated IGHV genes. Patients with an unmutated sequence have a worse outcome 
(Müller-Hermelink et al., 2008). The CNR1 high expression group showed also a shorter 
lymphocyte doubling time (LDT), with LDT under one year being associated with adverse 
prognosis (Müller-Hermelink et al., 2008). Finally, high CNR1 expression was associated 
with high CD38 expression. High CD38 expression is associated with worse clinical outcome 
(Malavasi et al., 2011). There was no association between CNR1 expression and any of the 
cytogenetic markers.  
Kaplan-Meier survival analysis revealed a significantly shorter overall and treatment free 
survival in the CNR1 high expression group. For progression free survival no significant 
correlation was found. All together, the data support that CNR1 high expression is a novel 
prognostic maker. Multivariate analysis demonstrated that CNR1 as prognostic marker was 
independent of CD38 expression, Binet stage and LDT, but associated with mutation status. 
On the other hand, while CNR2 is higher expressed in CLL patients, high mRNA expression 
was not associated with any of the tested prognostic marker. Also overall, treatment free and 
progression free survival was not significantly different when comparing high and low 
expressing groups. A higher expression of CNR2 in CLL compared to CNR1 was also found 
by Piszc et al. on the surface of neoplastic lymphocytes from CLL patients detected by flow 
cytometry (Piszcz et al., 2004). An explanation for the higher CNR2 expression might be that 
CLL is a disease of neoplastic B cells with an increase in the clonal B cells in the peripheral 
blood (Hallek et al., 2008). B lymphocytes show the highest CNR2 expression within normal 
PBMC (Mackie and Stella, 2006). Hence, the number of cells with high CNR2 expression is 
increased in CLL patients. The prognostic value of CNR2 was also tested in diffuse large B-
cell lymphoma (DLBCL). The analysis of 104 DLBCL samples in a tissue microarray found 
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no correlation between CNR2 expression and clinical outcome (Rayman et al., 2011). In 
contrast, for human hepatocellular carcinoma (HCC) a significant disease-free survival for 
patients with high CNR1 and CNR2 expression was demonstrated and both cannabinoid 
receptors correlated with two clinicopathological markers (Xu et al., 2006). The authors 
recommended both receptors as potentially prognostic factors.  
Since the present study revealed no association between CNR2 expression and survival, for 
CLL only the CNR1 expression seems to be of importance. 
The next aim was to evaluate whether the protein expression levels follow CNR1 and CNR2 
mRNA expression levels. In this study westernblots were used to determine protein 
expression in CLL patients with CNR1 high/low and CNR2 high/low mRNA expression levels. 
As positive control, recombinant CNR1 and recombinant CNR2 protein was used. Additional 
positive controls were the cell lines A-549 and JURKAT. A-549 cells, which only express 
CNR1, were used for the datatsheet of the CNR1 antibody from GENTEX and the JURKAT 
cells were already used by others as a positive control for CNR2 expression (Small-Howard 
et al., 2005). 
For CNR1 protein, it was difficult to detect bands of the correct size. The amino acid (AA) 
length of the CNR1 is 472AA (Howlett et al., 2002), therefore the predicted size is 53kDa 
(Daaka et al., 1996). Preliminary data led to the decision to use the polyclonal CNR1 
antibody from Thermo Scientific, since antibodies from two other manufacturers resulted in 
less intense bands at the predicted size (data not shown). In the datatsheet of the CNR1 
antibody used, the detection of one band at ~60kDa and lighter bands at ~23kDa, ~72kDa, 
~180kDa is reported. In fact, the antibody detected a big band at the calculated ~53kDa for 
the recombinant protein and a lighter band of the same size in A-549 cells. In the patients’ 
samples and other cell lines a band at the in the datasheet described 72kDa were also 
detected. In all samples, additional bands were detected at under 34kDa, 130kDa and 
170kDa, which were not reported in the datasheet. Other groups described similar problems 
for the detection of CNR1 at the calculated size (~53kDa) with the use of different polyclonal 
antibodies. Grimsey et al. tested a number of N-terminal CNR1 polyclonal antibodies from 
different manufactures and none detected bands between 53kDa and 60kDa (Grimsey et al., 
2008). Take together; this suggests an inherent problem regarding the detection of CNR1 
protein with the commercially available CNR1 antibodies. There are several possible 
explanations for the different band sizes. A slightly higher molecular weight than 53kDa could 
be explained by glycosylation. Three glycosylation sites at the N-terminus were reported for 
CNR1 (Shire et al., 1995). Larger band sizes than the detected 130 – 170kDa were also 
described by others. Wager-Miller et al. developed an antibody against CNR1 401-473AA, 
which detected bands at 53kDa, 60kDa as well as at 160kDa and 200kDa (Wager-Miller et 
al., 2002). They suggested that the high molecular weight forms were trimeric and tetrameric 
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forms of the CNR1 receptor. Another explanation could be that the CNR1 receptor builds 
dimers with other receptors. A study revealed that CNR1 exists as receptor complex with the 
Dopamin D2 receptor (Kearn et al., 2005). At a first thought, the bands, smaller than 53kDa 
might be due to splice variants of the CNR1, in addition to the full length CNR1, two splice 
variants were reported, CNR1a and CNR1b (Ryberg et al., 2005). Where CNR1a is 
described to be by 61AA shorter (Shire et a., 1995) and CNR1b shows an in-frame deletion 
of 33AA (Ryberg et al., 2005). Concerning the molecular weight, CNR1a has a calculated 
size of 45,9kDa and CNR1b of 49,1kDa   
(http://www.proteinatlas.org/ENSG00000118432/gene visited on 13.11.12). Thus, the splice 
variants cannot explain the detected bands at under 34kDa, which remain questionable.  
In order to compare protein and mRNA expression, two controls were used. As reported 
previously and as detected by us (Small-Howard et al., 2005; Datasheet CNR1 GENTEX), A-
549 cells do not express CNR2 mRNA and JURKAT cells lack CNR1 expression. Also other 
groups found that naive JURKAT cells express only low levels of CNR1 transcripts (Börner et 
al., 2007; Daaka et al., 1996). This might be changed by changing the activation status of the 
cell. Thus, CNR1 mRNA expression was enhanced in JURKAT cells after IL-4 (Interleukin-4) 
(Börner et al., 2007) or THC treatment (Börner et al., 2007). Bands of similar size were 
detected for the proteins of the two cell lines using the CNR1 antibody. Since only the CNR1 
and not the CNR2 recombinant protein showed an intense band at 53kDa, the used antibody 
seemed to be specific for CNR1, which would suggest that the CLL cells and the two cell 
lines do not express sufficient amounts of the protein to be detectable. In this study, although 
patients with both high and low CNR1 mRNA expression were tested, no association 
between mRNA expression and protein expression levels could be observed. Due to the 
problems in detection of bands at the correct size and the independence of band patterns 
from mRNA expression levels, the protein levels of CNR1 could not be evaluated.  
As for the CNR1, CNR2 high/low mRNA expressing patients were screened to determine the 
CNR2 protein expression in CLL. Similarly, the cell lines A-549 and JURKAT together with 
the recombinant CNR1 and recombinant CNR2 proteins were used as controls. 
Again, the westernblots revealed problems with regard to the detection of CNR2 protein. The 
amino acid length for the CNR2 is 360AA (Howlett et al., 2002), which predicts a size of 
38kDa for the protein (Small-Howard et al., 2005). In the datasheet a band at 39,7kDa is 
described for CNR2 (ABGENT) antibody, which corresponds with the ~40kDa band observed 
for the recombinant CNR2 protein. Although this antibody is monoclonal, additional bands at 
72kDa and 130kDa were detected with recombinant CNR2 protein. Since the antibody did 
not show any bands for the CNR1 recombinant protein, the detection of CNR2 protein 
seemed to be specific. In the cell lines JURKAT and A-549 and in the tested CLL samples 
similar bands were detected at 45kDa, 55kDa, 72kDa together with a light band at 40kDa.
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Considering that A-549 cells do not express CNR2 mRNA, it is rather unlikely that the CNR2 
antibody detected CNR2 protein only. Also for the CLL samples, no correlation could be 
observed between protein band intensity and mRNA expression level. The 40kDa band was 
more intense for the recombinant protein and less intense for all samples tested (cell lines 
and CLL samples), independent of mRNA expression level. One explanation could be that 
the cells do not express sufficient CNR2 protein for detection, and that protein expression 
might be enhanced in activated cells. For macrophages it could be shown that expression of 
CNR2 protein was undetectable in resident peritoneal macrophages, but that it was 
expressed to a high extent in thioglycolate-elicited macrophages (Carlisle et al., 2002). Since 
in macrophages protein expression appeared to follow mRNA expression (Carlisle et al., 
2002), and in this study protein expression was not associated with mRNA expression, the 
problem might not be due to low protein expression but to the antibody used. This leads to 
the question what the monoclonal antibody detects at 45kDa, 55kDa, 72kDa and 130kDa. A 
second isoform of CNR2 has been reported which is expressed to another extent in different 
tissues (Liu et al., 2009). Still, CB2 antibodys that are commercial available, could not 
distinguish the two isoforms (Liu et al., 2009) and the predicted size, referring to the human 
protein atlas is for both splice variants 39,7kDA   
(http://www.proteinatlas.org/ENSG00000188822/gene visited 13.11.12). Another explanation 
might be the sequence homology between the two receptors. Both receptors show 68% 
amino sequence homology within the transmembrane domain and 44% throughout the whole 
protein (Jean-Gilles et al., 2010). The data suggest that the CNR2 antibody also detects the 
CNR1 protein, due to the bands at 45kDa, 55kDa, 72kDa and 130kDa, since for CNR1 
recombinant protein bands were also detected at 52kDa, 72kDa and 130kDa.  
In conclusion, using westernblot for direct protein detection of CNR1 and CNR2 it was not 
possible to detect an association between mRNA level and protein level. While in prostate 
cancer, the two cannabinoid receptors are expressed to a higher extent than in normal 
prostate epithelial cells (Olea-Herrero et al., 2009), in CLL an enhanced expression of the 
CNRs on protein level could not be shown. In future experiments, the specificity of the 
antibodies could be tested by using blocking peptides as described by Blazquez (Blázquez et 
al., 2006). Further solutions to overcome the detection problems with the available antibodies 
might be to evaluate downstream activation in the signal cascade of the cannabinoid 
receptors. Thus, to test whether an mRNA increase of CNR1 after receptor activation is 
followed by an increase in CNR1 protein, CNR1 mediated MAPK phosphorylation was 
detected by westernblot (Börner et al., 2007). 
The third aim of the study was to evaluate the cytotoxic effect of CNR1 and CNR2 specific 
agonists and antagonists on cell lines per se and with regard to CNR1 and CNR2 expression 
levels. MEC-1 and MEC-2 were used, since they are CLL cell lines (Stacchini et al., 1999). 
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A-549 and JURKAT were used as positive controls for CNR1 and CNR2, respectively. For all 
tested cell lines there was a time and concentration depended reduction in viability, with a 
difference in sensitivity between the cell lines. The exception for a time dependent effect was 
(-)-Cannabidiol, the compound most effective overall in the study, for which similar IC50 
values were determined for the two incubation times. A time dependent drop was also shown 
for ACEA, AM251 and AM630 in human pancreatic cancer cells (Fogli et al., 2006). 
Differences in sensitivity were reported by two groups. A much lower IC50 was found for (R)-
(+)-Methandamide after 48h incubation in a human prostate cell line, with ~50µM for the cell 
lines in this study and 10µM for the prostate cell line (Olea-Herrero et al., 2009). JWH133, 
which showed high IC50 values in this study (~50µM), inhibited already significantly at a 
concentration of 100nm the secretion of IL12-p40 by LPS/INFγ stimulated macrophages 
(Correa et al., 2005).  
In the cell lines studied here, no clear association between mRNA expression levels and 
sensitivity could be observed. JURKAT cells, which do not express CNR1, had a comparable 
IC50 for the CNR1 agonist ACEA compared to MEC-1 and MEC-2 that express both 
cannabinoid receptors. A-549 cells which only express CNR1 displayed the highest reduction 
in viability, but only after 48h. Overall, these cells were the least affected cell line cells in this 
study. (R)-(+)-Methanadamide, the analogue of the endocannabinoid anandamide and a 
CNR1 agonist (Pertwee, 2006), and JWH-133, CNR2 agonist (Pertwee, 2006), showed the 
highest IC50 values in all four cell lines. These data would suggest that cannabinoids that act 
only on one of the two cannabinoid receptors are less cytotoxic. However, this is in contrast 
to another study, where MEC-1 and MEC-2, which express both receptors to some extent, 
were more affected by (R)-(+)-Methandamide than cell lines with either low CNR1 or CNR2 
expression (SK-MM-2; Raji, Namalwa) (Gustafsson et al., 2008). In addition, ACEA, a 
selective CNR1 agonist (Hillard et al., 1999) and a compound that acts only on one receptor, 
such as JWH133 and (R)-(+)-Methandamide, showed even lower IC50 values than JWH133 
and (R)-(+)-Methandamide. (-)-Cannabidiol was the most effective compound in this study, 
and, considering that this compound acts as inverse CNR2 agonist and CNR1 antagonist 
(Thomas et al., 2007), one would assume that this could be due to the fact that it acts on 
both receptors. On the other hand, AM251 was more effective than AM630, at least in   
MEC-1 and MEC-2 cells. Considering that AM630 acts as CNR2 antagonist (Pertwee et al., 
1995), as inverse CNR2 agonist and weak CNR1 agonist (Ross et al., 1999), and as inverse 
CNR1 agonist (Landsman et al., 1998), thus influencing both receptors, while AM251 only 
antagonizes CNR1, the hypothesis that compounds acting on both receptors have higher 
impact on cells definitely is not straight forward. 
All together, the data suggest both a cell type specific and a compound specific cytotoxic 
activity regardless of mRNA expression. A reason for the independence of viability reduction 
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from mRNA level could be differential regulation of protein expression after translation in 
different cell types, which would not be detected on the mRNA level and which would have 
escaped detection in this study due to unspecificity of the antibodies available. Another 
reason for the independence of sensitivity from mRNA expression levels could be that 
cannabinoids do not exert their function restricted to the cannabinoid receptors. For AM251 
and AM630 it was shown that they also act via TRP channels (Patil et al., 2011). Also,  
(-)-Cannabidiol was shown to act on the vanilloid receptor TRPV1 by generating a TRPV-1 
receptor mediated intracellular calcium elevation in TRPV1 transfected HEK293 cells 
(Ligresti et al., 2006).  
The concentrations needed for an effective inhibition of viability for all compounds were 
highly variable resulting in IC50 values mostly larger than ~15µM. In this respect, it has been 
reported that cannabinoids are less effective in serum containing medium than in serum free 
medium which could be the result of an interaction between the drugs and albumin. Thus, 
over 99% of the plasma endocannabinoid anandamide is bound to albumin. Also, BSA 
showed a high affinity binding site for anandamide (Bojesen and Hansen, 2003). In addition, 
serum has been described to protect against apoptosis based on its nutrition composition 
(Zanghi et al., 1999), consequently cells are higher susceptible to cytotoxic agents in serum-
free medium. In mantle cell lymphoma (MCL), anandamide and the synthetic cannbinoid 
WIN-55,212-2 were more effective in lower serum concentrations (Flygare et al., 2005). The 
same was observed by Richardson et al, MCL cells were less sensitive to THC under natural 
conditions with 10% serum than under serum-free conditions (Richardson et al., 2007).  
Which precise pathway was involved in the reduction in viability in this study was not tested. 
In the literature, different pathways have been reported to be involved in cannabinoid 
signalling depending on the cells. In melanoma cells the incubation with cannabinoids 
inhibited AKT, a key element in prosurvival pathway that is deregulated in many tumours, 
whereas ERK, JNK, p38 MAPK were not affected (Blázquez et al., 2006). Analysing the gene 
expression profile after AM251 treatment in MIA PaCa-2 cells revealed that this antagonist 
affects JAK/STAT, MAPK and cell cycle related pathways (Fogli et al., 2006). THC in 
leukemic cell lines act on the MAPK pathway by deactivation of ERK2 (Powles et al., 2005) 
and the treatment of MCL with (R)-(+)-Methanandamide induced cell death via an increase in 
ceramide by upregulation in the de novo ceramide synthesis pathway (Gustafsson et al., 
2009). 
In addition to cell lines, primary cells from CLL patients were incubated in suspension and in 
coculture with the cannabinoids. For the evaluation of the cannabinoids as therapeutic 
substances also PBMC from healthy donors (HD) were screened and therefore incubated in 
suspension for 48h. Comparing 48h incubations in suspension culture, CLL primary cells 
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were more sensitive towards (R)-(+)-Methandamide and the antagonists AM251 and AM630 
compared to the CLL cell lines MEC-1 and MEC-2, whereas they showed higher IC50 for 
ACEA and JWH133. These different results show that for evaluating the potentials of 
cannabinoids in therapy, the testing of cell lines instead of primary cells is but just a first step. 
In addition, the primary cells showed higher standard deviations than the cell lines due to 
biological variation between single patients. In healthy donors, all compounds except (R)-(+)-
Methandamide displayed IC50 values similar to CLL patients. Comparable data were 
observed for THC, cell death occurred at similar concentrations in leukemia cell lines and 
non-malignant cells (Powles et al., 2005). This stands in contrast to other studies where  
(-)-Cannabidiol at concentrations, which corresponded to the IC50 values of epithelial cells 
derived from various tumours, had no cytotoxic effect on non-tumour cell lines (human 
keratinocytes, rat preadipocytes, mouse monocyte-macrophages) (Ligresti et al., 2006). 
Furthermore, Shrivastava et al showed that (-)-Cannabidiol induced cell death in breast 
cancer cells but was significantly less effective on non cancer cell lines (MCF10-A) 
(Shrivastava et al., 2011). 
To take into account the protective effect of the microenvironment for CLL cells, CLL 
samples were also tested in coculture with the mouse fibroblast cell line M2-10B4. Overall, 
CLL cells in suspension were more susceptible towards most cannabinoids compared to 
experiments in coculture. Only two of the tested compounds, (-)-Cannabidiol and (R)-(+)-
Methanandamide, had similar influence on the cells in suspension and in coculture. CLL 
primary cells undergo spontaneous apoptosis when cultured in absence of microenvironment 
(Hegde et al., 2008). Also, M2-10B4 and human marrow stromal cells protect CLL from 
spontaneous and drug induced apoptosis equally effective (Kurtova et al., 2009). In other 
studies it was demonstrated that after 48h under standard culture conditions only 50% of 
CLL cells remained viable whereas in coculture with M2-10B4 viability was enhanced up to 
81% (Buchner et al., 2010). This protective effect of M2-10B4 is due to the expression of pro 
survival signals for the CLL cells. Thus, vimetin provides anti-apoptotic signals to CLL cells 
through the BCR (Binder et al., 2010). Other protective effects of the microenvironment are 
Notch ligands which are expressed by MSC (Seke Etet et al., 2012) and hedgehog proteins 
produced by stromal cells that promote survival in CLL cells in vitro (Hegde et al., 2008). To 
determine to which degree the particular resistance of CLL samples in coculture was 
associated with the sensitivity of M2-10B4 toward cannabinoids, the mouse fibroblasts were 
tested alone. For ACEA, JWH133 and AM251 IC50 values were not reached similar to 
incubations of CLL cells in coculture with M2-10B4. For AM630 the IC50 value was higher, 
but for (-)-Cannabidiol and (R)-(+)-Methanandamide the IC50 values were similar to primary 
CLL cells. This would explain, why no difference between IC50 values of primary CLL cells 
between suspension and coculture assays for (-)-Cannabidiol and (R)-(+)-Methanandamide 
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could be observed. As mentioned earlier, (R)-(+)-Methandamide was the only tested 
compound with a lower impact on HD cells than on CLL cells. Since M2-10B4 cell incubation 
revealed a strong effect of (R)-(+)-Methandamide on these feeder cells, it still needs to be 
tested how strong this compound affects human stromal cells compared to mouse fibroblasts 
for better evaluation of the therapeutic potential of this substance.  
Whether the reduction in viability was due to a direct induction of apoptosis or other 
physiological changes was not studied here. Other groups showed that (R)-(+)-
Methanandamide directly induced apoptosis and cell death in cell lines representing MCL 
and CLL (MEC-1 and MEC-2) (Gustafsson et al., 2008). 
 
 
Figure 27: CLL primary cells incubated with fludarabin. 
Primary CLL PBMCs were incubated with different concentrations of fludarabin in suspension and 
coculture (M2-10B4) for 48h. Data were provided by Clemens Pausz. 
 
Compared to other compounds, relatively high cannabinoid doses are needed for 
comparable effects on viability. For comparison figure 27 depicts primary CLL cells incubated 
with fludarabine, a standard chemotherapeutic drug in CLL. For this compound IC50 values 
of 4,18µM in suspension and 5,36µM in coculture could be reached, whereas for (R)-(+)-
Methanandamide 29,27- 33,19µM were determined. Thus, cannabinoids have only limited 
use as novel chemotherapeutics, in particular since the administration of cannabinoids into 
the body is difficult. Oromucosal uptake of cannabinoids is lower than by inhaling, in addition 
drug absorption depends on the inhaling technique. For THC the total amount of absorption 
is 10-30% (Karst et al., 2010), however, inhalation might lead to lung impairment (Karst et al., 
2010). High doses would be needed which might lead to side effects. In human studies using 
cannabinoids for chronic pain, adverse effects were sedation, dizziness, cognitive 
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impairment, anxiety and dry mouth, these effects increased with higher dosages (Karst et al., 
2010). Thus, rimonabant, a CNR1 antagonist/inverse agonist, used in treating obese people 
was withdrawn from the market, due to its side effects (Ward and Raffa, 2011). Furthermore, 
the cytotoxic effect of THC in MCL cells in vitro was low when using concentrations close to 
the real achievable plasma level (Richardson et al., 2007). On the other hand, dronabinol 
(Marinol) and nabilone are administered as capsules (Velasco et al., 2012) and are approved 
and already used successfully for stimulation of appetite in AIDS patients (dronabinol) and 
for the suppression of nausea and vomiting during chemotherapy (nabilone) (Pertwee, 2008). 
Still, the use of cannabinoids in anti-cancer therapy thus is questionable.  
Also in primary cells it was tested whether high CNR1 or CNR2 mRNA expressing patients 
were more sensitive to cannabinoids than CNR1/CNR2 low expressing patients. Similar to 
the cell lines there was no correlation between mRNA expression levels of the two 
cannabinoid receptors and susceptibility to the compounds of the primary cells. As 
mentioned earlier, others showed that high cannabinoid receptor expressing cells are more 
affected than low expressing cells. The viability of Rec-1 cells with high CNR1 expression 
was significantly reduced after 48h 10µM anandamide treatment whereas SKMM-2 cells, 
which do not express CNR1, remained unaffected (Flygare et al., 2005).  
However, also the opposite - drug activity independent of CNR expression - has been 
reported in the literature. Thus, (-)-Cannabidiol induced apoptosis in activated hepatic stellate 
cells which could not be blocked by either AM251 or AM630 (Lim et al., 2011). The same 
independence of (-)-Cannabidiol from cannabinoid receptor expression was seen for the 
human glioma cell lines U87 and U373 (Massi et al., 2004) and for breast cancer cells 
(Shrivastava et al., 2011).  
Although binding also on CNR1 and CNR2, it was reported that (-)-Cannabidiol mainly acts 
as antagonist to GPR55 (Ryberg et al., 2007) and as weak agonist of VR1 vanilloid receptors 
(Costa et al., 2004). Finally, also Powles et al found that cannbinoid receptor expression 
levels did not correlate with cytotoxic response to THC in CEM, HEL-92 and HL60 cell lines 
(Powles et al., 2005). In CLL the microenvironment protects cancer cells from spontaneous 
and drug-induced apoptosis (Burger et al., 2009). Especially the interaction of CXCL12 and 
CXCR4 contributes to the drug resistance (Burger and Kipps, 2006). Stromal cells and NLCs 
secrete CXCL12, which signals through the chemokine receptor CXCR4 (Burger and Kipps, 
2006), so that CLL cells are attracted to niches where these feeder cells provide them with 
pro-survival signals (Burger et al., 2009). CLL cells express a high amount of the CXCR4 
(O´Callaghan et al., 2012; Burger and Kipps, 2006), which was also revealed in the FACS 
analysis in this study. Considering that cannabinoids were reported to interfere with 
CXCL12/CXCR4 interaction (Ghosh et al., 2006), it was tested in coculture whether 
cannabinoids exert an additive effect with fludarabine, the CXCR4 specific inhibitor 
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AMD3100 (O´Callaghan et al., 2012) was used as positive control. Highest impact on viability 
had AMD3100 alone which was even stronger than fludarabine itself. Compared to 
fludarabine, cannabinoids exerted only a small impact on the viability of primary CLL cells. In 
addition, all tested cannabinoid agonists and antagonist showed only a small or even non 
additive effect with fludarabine. This indicates that a) cannabinoids are not suited for 
combination therapy with fludarabine in CLL, and b) in contrast to observations in JURKAT 
cells, cannabinoids do not interfere with the CXCL12-CXCR4 axis in chronic lymphocytic 
leukemia. In contrast, AMD3100, also known as plerixafor, was shown to decrease the 
expression of CXCR4 (Stamatopoulos et al., 2011). The observed viability reducing effect of 
AMD3100 was also described by others. Buchner et al. described the used M2-10B4 as 
CXCL12 secreting cells. They also found that AMD3100 reversed the protective effect of M2-
10B4 which led to a reduction in viability. They also showed that CLL cell survival was not 
affected by AMD3100 in the absence of M2-10B4 (Buchner et al., 2010). A similar result was 
observed by Stamatopoulos et al. They showed that when mononuclear cells (MNC) from 
CLL patients were cultured alone, AMD3100 did not have a significant effect on apoptosis or 
viability but significantly decreased the viability when cells were cultured with AMD3100 
under microenvironmental conditions (Stamatopoulos et al., 2011). 
The final aim of this study was to investigate the effect of cannabinoids in interference with 
CLL cell migration. It was tested whether CLL cells expressing the CXCR4 migrate toward 
the ligand CXCL12 and how incubation with cannabinoids alters the migration behaviour. 
The results revealed that CLL primary cells migrate towards CXCL12, with cell migration 
significantly reduced when no CXCL12 was available.The migration of CLL cells toward 
CXCL12 was also described by O`Hayre et al. Furthermore, they reported that B cells from 
healthy donors show an even higher migration than cells from CLL patients (O’Hayre et al., 
2010). Migration was reduced strongly after AMD3100 incubation, an effect also described 
by Stamatopolous et al. Pre-incubation of MNC of CLL patients resulted in a marked 
decrease of migration in response to CXCL12 (Stamatopoulos et al., 2011). This interruption 
of the CXCR4/CXCL12 axis is of interest in therapy since it renders malignant cells more 
susceptible to cytotoxic agents. AMD3100 is already clinically used in combination with 
granulocyte-colony stimulation factor (G-CSF) to enhance the mobilization of stem cells for 
transplantation in patients with non-Hodgkin lymphoma (NHL) (O´Callaghan et al., 2012; 
Pusic and DiPersio, 2010). Furthermore there is an ongoing Phase I /II study assessing the 
role of AMD3100 as sensitizing agent in patients with CLL treated with rituximab (Pusic and 
DiPersio, 2010). 
In migration assays it was tested whether cannabinoids could be an equally promising 
substance in this interference with the protective environment. In contrast to AMD3100, 
however, and as already indicated by the combination experiments with fludarabine, the 
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incubation with cannabinoids did not significantly reduce migration, although other groups 
showed that cannabinoids may have a function in migration. 
The CNR2 agonist JWH015 inhibited CXCL12 induced chemotaxis, therefore the authors 
proposed that CNR2 might cross talk with CXCR4 (Nasser et al., 2011). WIN55,212-2 was 
shown to induce mouse splenic lymphocyte migration toward CXCL12 but to inhibit migration 
at high doses (Tanikawa et al., 2011). Thus the cannabinoid concentration could play an 
important role, especially since higher doses exert a cytotoxic effect. Pre-incubation with a 
cannabinoid antagonist before the agonist incubation, did not enhance and did not reduce 
migration in our study. While the treatment of non-small lung cancer cells (NSCLC) with 
WIN55,212-2 and JWH-015 inhibited chemotaxis in vitro, this was attenuated by pre-
treatment with the antagonists AM251 and AM630 (Preet et al., 2011). Such an effect was 
also shown for the JURKAT T cell line (Ghosh et al., 2006). Incubation with the CNR2 
agonist JWH-015 inhibited the CXCL12 induced chemotaxis; pre-incubation with AM630 
partially reversed the inhibitory effect of JWH-015 in migration (Ghosh et al., 2006). Gosh et 
al. used the same agonist concentration of 10µM (Ghosh et al., 2006). Instead of JWH-015 
used by Gosh et al., in the recent study JWH133 was used, for which a similar cytoxicity can 
be supposed. In addition the inhibition of migration with JURKATS was reached for 10µM 
JWH133 in the recent study (data not shown). Therefore, an inhibition of migration for CLL 
with 10µM JWH133 was expected. However, this could not be shown for CLL cells. Gosh et 
al. had the highest reversal of the inhibititory effect of JWH-015 for 0,25µM AM630 (Ghosh et 
al., 2006). In the present study, 0,1µM of the antagonist AM630 was used. Since a higher or 
lower concentrations of the antagonist had no effect in the Gosh study (Ghosh et al., 2006), 
the concentration of 0,1µM might have been to low for an affect. However, neither the 
incubation with the agonist (JWH133) nor the incubation with the antagonist (AM630) 
influenced the CLL migration toward CXCL12. Therefore, it could not be supposed that the 
combination of both compounds might exert an effect, as shown for the JURKATS (Ghosh et 
al., 2006). Summarizing, although cannabinoids have been reported to play a role in the 
interaction with cell-cell cross-talk, they did not interrupt the protective effect of the 
microenvironment in CLL cells, neither did they show an appreciable additive effect with the 
therapeutic drug fludarabine. The concentrations needed for a cytotoxic effect on CLL cell 
viability were much higher than for fludarabine. Importantly, they exert a similar toxic impact 
on healthy cells. In contrast to other studies, it has to be concluded that the usefulness of the 
tested synthetic cannabinoids as therapeutic drugs in CLL is questionable. The mRNA 
expression of cannabinoid receptor 1, however, could be determined as a novel and reliable 
prognostic marker. 
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APPENDIX 
 
Appendix 
 
I. List of abbreviations 
 
APS     Ammonium Persulfate 
BSA     Bovine Serum Albumine 
 
Cannabinoide: 
(R)-(+)-Methanandamide  (R)-N-(2-Hydroxy-1-methylethyl)-5Z,8Z,11Z,14Z 
     eicosatetraenamide 
AMD3100 octahydrocholride  1,1`-[1,4-Phenylenebis-(methylene)]-bis-(1,4,8,11 
     tetraazacyclotetradecane) octahydrochloride 
ACEA     N-(2-Chlorethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide 
JWH133 (6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-
tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran 
(-)-Cannabidiol 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-
1-yl]-5-pentyl-1,3-benzenediol 
AM251  N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl) 4-methyl-1H-pyrazole-3-carboxamide 
AM630  6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-
yl](4-methoxyphenyl)methanone 
 
DEPC     Diethyl pyrocarbonate 
DMEM     Dulbecco`s Modified Eagle`s Medium 
DMSO     Dimethyl sulfoxid 
NaN3     Sodium azide 
Na-deoxycholate   Sodium-deoxycholate 
EDTA     Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N`,N`-
tetraacetic acid 
FCS     Fetal Calf Serum 
HCl     Hydrochlorid acid 
NaCl     Sodium chloride 
NaF     Sodium fluoride 
PBMC     Peripheral Blood Mononuclear Cells 
PBS     Phosphate Buffered Saline
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RPMI medium    Roswell Park Memorial Institute medium 
RT     Room temperature 
SDS     Sodium dodecyl sulfate 
Tris      Tris(hydroxymethyl)aminomethane 
 
II. Material 
 
ABI Prism 7000 SDS Software    [Applied Biosystems] 
ABI Prism 7000 Sequence Detector    [Applied Biosystems] 
CellQuest Pro Software     [Becton Dickinson] 
CELLSTAR Cell Culture Flasks    [Greiner Bio-One] 
Centrifuge Allegra X-12R     [BECKMAN COULTER] 
Centrifuge 5417c      [Eppendorf] 
Centrifuge Universal 32R     [Hettich] 
Combitip       [Eppendorf] 
Counting chamber      [BRAND] 
CRYO STORAGE VESSEL BSS-4800   [VWR] 
EasySep® kit       [StemCell Technologies] 
Electrophoresis power supply E455    [CONSORT] 
Excel 2003       [Microsoft] 
FACScan       [Becton Dickinson] 
FACS tubes       [Becton Dickinson] 
Freezer -80°C       [Thermo Scientific] 
Gel Blot Paper       [WHATMAN] 
GraphPad Prism5      [GraphPad Software, Inc.] 
Immobilon-FL Transfermembran    [MILLIPORE] 
Incubator Heraeus      [Thermo Scientific] 
Kimwipes       [Kimberly-Clark] 
Medline freezer -20°C     [LIEBHERR] 
Medline fridge 4°C      [LIEBHERR] 
Microprocessor pH537     [WTW] 
Microscope Axiovert 40C     [ZEISS] 
MicroAmp Optical Adhesive Film    [Applied Biosystems] 
MikroWin 2000      [Berthold Technologies] 
Mini-PROTEAN Tetra Electrophoresis System  [BIO-RAD] 
Mini Trans-Blot® Electrophoretic Transfer Cell  [BIO-RAD] 
Multipette® Plus      [Eppendorf]
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NanoDrop 8000      [Thermo Scientific] 
NanoDrop 8000 V.2.1.0.     [Thermo Scientific] 
Odyssey Imager       [LI-COR] 
Odyssey software V3.0     [LI-COR] 
Pierce BCA Protein Assay Kit    [Thermo Scientific] 
Pipettor Easypet      [Eppendorf] 
Reaction tubes      [Eppendorf] 
Polycarbonate Membrane Transwell Inserts  [CORNING] 
Research® Pipette      [Eppendorf] 
Safety cabinet HERAsafe     [Thermo Scientific] 
Safe-lock tubes      [Eppendorf] 
SafeSeal Tips       [Biozym] 
Semi-Skirted 96-Well PCR Plate    [STARLAB] 
SPSS Statistics Version 20     [IBM] 
Stripette® pipets      [CORNING] 
Thermomixer        [Eppendorf] 
TriStar LB941       [Berthold Technologies] 
Vortex mixer L24      [Labinco] 
96 Well Polystyrene Microplates    [Greiner Bio-One] 
12 Well tissue culture treated    [Greiner Bio-One] 
24 Well cell culture cluster     [CORNING] 
 
III. Chemicals 
 
Antibodies: 
Alexa Fluor488 goat anti-mouse IgG (H+L)   [Invitrogen] 
Anti-CNR1 polyclonal Antibody    [Thermo Scientific #PA1-745] 
Anti-CNR2 monoclonal Antibody    [ABGENT #AF1575a] 
Anti-GAPDH monoclonal Antibody    [CALBIOCHEM #CB1001] 
IRDye 680 Conjugated Goat Polyclonal Anti- Mouse IgG (H+L)   [LI-COR #926-32220] 
IRDye 800CW Conjugated Goat Polyclonal Anti-Rabbit IgG (H+L) [LI-COR #926-32211] 
PE Mouse Anti-Human CD184    [BD Pharmigen #555974] 
Purified Mouse IgG2a, κ Isotype Ctrl   [BioLegend #401501] 
 
A/B Bis-Acrylamid      [NATIONAL DIAGNOSTICS] 
APS        [SERVA] 
Aqua bidest        [Braun]
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Benzamidine       [SIGMA] 
 
Cannabinoids: 
ACEA        [TOCRIS] 
AM251       [TOCRIS] 
AM630       [TOCRIS] 
(-)-Cannabidiol      [TOCRIS] 
JWH133       [TOCRIS] 
(R)-(+)-Methanandamide     [TOCRIS] 
 
AMD3100 octahydrocholride     [TOCRIS] 
Albumin from bovine serum     [SIGMA] 
CellTiter-Blue®      [PROMEGA] 
Chloroform       [MERCK] 
CNR1 (Human) Recombinant Protein    [# H00001268-G01 ABNOVA] 
CNR2 (Human) Recombinant Protein   [# H00001269-G01 ABNOVA] 
25x Complete       [ROCHE] 
DEPC        [SIGMA] 
DMSO        [SIGMA] 
dNTP Mix U1515      [Promega] 
EDTA        [CALBIOCHEM] 
EGTA        [SIGMA] 
Ethanol       [VWR] 
Ficoll (Biocoll)       [BIOCHROM] 
Fludarabine       [SIGMA] 
Isopropanol       [FLUKA] 
GIBCO DMEM      [Life Technologies] 
GIBCO DMEM (free of phenolred)    [Life Technologies] 
GIBCO FCS Gold      [Life Technologie] 
GIBCO PBS       [Life Technologies] 
GIBCO RPMI1640      [Life Technologies] 
GIBCO RPMI1640 (free of phenored)   [Life Technologies] 
Glycerol       [CALBIOCHEM] 
ß-Glycerophosphate      [FLUKA] 
Glycine       [MERCK] 
HCl        [SIGMA] 
ß-Mercaptoethanol      [SIGMA]
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Methanol       [SIGMA]  
Mikrozid       [Schuelke] 
MilliQ water       [MILLIPORE] 
M-MLV Rev. Transcriptase M1705    [Promega] 
NaCl        [SIGMA] 
Na-deoxycholate       [SIGMA] 
NaF        [SIGMA] 
NaN3        [SIGMA] 
Na-Orthovanadate      [SIGMA] 
Non-fat dry milk 
Nonidet P-40       [USB] 
Oligo (dT) 15 Primer C1101     [Promega] 
Orange G       [SIGMA]  
Penicillin / Streptomycin     [PAA] 
peqGOLD Protein-Marker IV     [PEQLAB] 
Recombinant Human CXCL12    [R&D Sytems #350-NS] 
5x Reaction Buffer      [Promega] 
RNAsin® Plus  N2611     [Promega] 
SDS         [BIO-RAD] 
TaqMan® Gene Expression Assays    [Applied Biosystems] 
TaqMan® Universal Master Mix    [Applied Biosystems] 
Temed        [BIO-RAD] 
Tetrasodium Pyrophosphate     [SIGMA] 
Tris        [SIGMA] 
Tris-HCl       [BIO-RAD] 
TRIzol        [Life Technologies] 
Trypanblue       [SIGMA] 
Trypsin-EDTA       [PAA] 
Tween20       [SIGMA]  
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Cannabinoids are the active compounds of the marijuana plant Cannabis sativa L.  
For hundreds of years, these plant derived phytocannabinoids have been used for medical 
indications, in particular for their psychoactive properties, and a number of synthetic 
cannabinoids with similar activity have been developed in recent years. They exert their 
function by binding the two cannabinoid receptors, CNR1 and CNR2, as agonist, antagonist 
or inverse agonist. Of the two receptors, CNR1 is mostly expressed in the nervous while 
CNR2 mainly is found in the immune system. Clinical applications for cannabinoids are, for 
instance, the suppression of nausea and vomiting in patients during chemotherapy, or the 
stimulation of appetite in AIDS patients. In addition, various studies reported that 
cannabinoids induce apoptosis and inhibit cell proliferation, invasion, and metastasis and 
block angiogenesis in solid tumors. Similar antiproliferative effects were observed in non-
Hodgkin lymphomas.  
Chronic lymphocytic leukemia (CLL) is a non-Hodgkin lymphoma and the most prevalent 
leukemia of adults in Western countries. The clinical course is heterogeneous, and standard 
therapeutic regimens consist of chemo- or immuno-chemotherapy. But one third of patients 
never responds to treatment, progress rapidly and succumbs to the disease. Great progress 
has been made in the development of therapeutics in recent years. However, in particular for 
these high risk patients novel therapeutic options are urgently needed.  
Considering the cytotoxic effects reported for cannabinoids and the need for therapeutic 
drugs in CLL, we wanted to study the cannabinoid receptors and the effect of their ligands in 
this malignancy in more detail. A cohort of 102 well characterized patients was screened by 
real time PCR for CNR1 and CNR2 mRNA expression. Expression was calculated relative to 
the mean of CD19 sorted healthy cells. Protein expression was analyzed in selected 
samples. Cell lines and peripheral blood mononuclear cells (PBMC) from CLL patients and 
healthy donors were incubated with cannabinoids in different concentrations and in 
comparison to fludarabine to establish cytotoxic efficacy. IC50 values were calculated based 
on standard viability assays. Both cannabinoid receptors were over-expressed in the study 
cohort. Whereas CNR2 mRNA expression did not correlate with any bad prognostic marker, 
high CNR1 mRNA expression was associated with advanced Binet stage (p-value = 0,049), 
unmutated IGHV (p-value = 0,006) and high CD38 expression (p-value = 0,032).   
Furthermore, CNR1 high expressing patients had a shorter overall survival (p-value = 0,002) 
and treatment free survival (p-value = 0,000). Protein expression levels could not be 
analyzed, due to the lack of specificity of the commercially available CNR1 and CNR2 
antibodies. In a first step, the tumor cell lines MEC-1, MEC-2 (both CLL), JURKAT (T-cell 
acute leukemia), and A-549 (lung carcinoma) were incubated with R-(+)-Methanandamide, 
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ACEA, (-)-Cannabidiol, JWH133, AM251, and AM630 at different concentrations. In these 
cell lines, a time and dose dependent decrease in cell viability could be determined. 
Differences in sensitivity between cell lines was observed, which were, however, not 
associated with CNR1 and CNR2 mRNA expression levels. Next, PBMC from CLL patients 
were incubated with the compounds both in suspension and in a pre-clinical, coculture model 
using the mouse fibroblast cell line M2-10B4. In suspension, comparing the CLL with the cell 
lines MEC-1 and MEC-2, the primary cells were similar susceptible to ACAE, less for 
JWH133 and (-)-Cannabidiol and more affected by the other three compounds. The coculture 
with the feeder cells exerted a protective effect, except for the incubation with (R)-(+)-
Methanandamide and (-)-Cannabidiol. These two compounds had also a toxic effect on the 
M2-10B4 cells. Similar cytotoxic effects of the tested cannabinoids were observed in healthy 
donor PBMC except for R-(+)-Methanandamide. 
Finally, emphasize was put on the microenvironment, particular the CXCR4/CXCL12 axis, 
which has been shown to contribute to survival of leukemic cells. Cannabinoids have been 
implicated in interfering with this chemokine axis in T cells. Therefore the additive effect of 
cannabinoids with fludarabine was explored and compared to the impact of AMD3100, a 
CXCR4 targeting compound with experimental usage in therapy. In inhibiting cell viability, 
cannabinoids were less effective compared to AMD3100 and exerted only a small additive 
effect when tested in combination with fludarabine. Finally, the effect of cannabinoids on the 
migration of CLL cells, expressing the CXCR4, toward the CXCL12 ligand was evaluated. In 
contrast to AMD3100, the cannabinoids did not exert a significant inhibiting effect on the 
migration of the primary CLL cells towards CXCL12.  
Referring to the low impact of cannabinoids on microenvironment in survival and migration 
and the similar cytotoxic effect on CLL cells and healthy cells, cannabinoids seem to be a 
poor therapeutic substance in CLL. Although the mRNA expression of CNR2 is not of 
prognostic value, the CNR1 mRNA expression levels could be established as new prognostic 
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Cannabinoide sind die aktiven Inhaltsstoffe der Cannabispflanze Cannabis sativa L.. Diese 
aus der Pflanze stammenden Phytocannabinoide wurden, besonders aufgrund ihrer 
psychoaktiven Eigenschaften, schon vor hunderten von Jahren in der Medizin angewandt. In 
den vergangen Jahren wurden diverse synthetischen Cannabinoide mit ähnlicher Wirkung 
entwickelt. Sie üben ihre Funktion aus indem sie als Agonist, Antagonist oder inverser 
Agonist an die zwei Cannabinoidrezeptoren CNR1 und CNR2 binden. Dabei wird CNR1 
hauptsächlich im Nervensystem exprimiert, während man CNR2 meist im Immunsystem 
findet. In der Klinik werden Cannabinoide bereits gegen Übelkeit und Erbrechen bei 
Chemotherapiepatienten und zur Appetitstimulation von AIDS Patienten eingesetzt. Zudem 
wurde in verschiedenen Studien die Wirkung von Cannabinoiden bei soliden Tumoren 
beschrieben. Sie inhibieren Apoptose, Zellproliferation, Invasion, Metastase und blockieren 
Angiogenese. Ähnliche anti-proliferative Wirkungen wurden auch bei non-Hodgkin 
Lymphomen beobachtet.  
Chronische lymphatische Leukämie (CLL) ist ein solches non-Hodgkin Lymphom und die 
häufigste Leukämie bei Erwachsenen in westlichen Ländern. Der klinische Verlauf ist sehr 
heterogen. Die Standardtherapie besteht aus Chemo- oder Immuno-chemotherapie. Ein 
Drittel der Patienten reagiert jedoch nicht auf die Behandlung, und erliegt nach schneller 
Progression der Erkrankung. Obwohl in den vergangen Jahren große Fortschritte in der 
Entwicklung von Therapien gemacht wurden, werden für die Hoch-Risiko-Patienten neue 
Therapiemöglichkeiten dringend benötigt. Daher und wegen der berichteten cytotoxischen 
Effekte der Cannabinoide, wollten wir die Cannabinoidrezeptoren und ihre Liganden in der 
CLL genauer studieren. Eine Kohorte von 102 gut charakterisierten Patienten wurde in einer 
real time PCR auf CNR1 und CNR2 mRNA Expression untersucht. Die Expression wurde 
relative zum Mittelwert von CD19 sortierten gesunden Zellen berechnet. Zudem wurde in 
ausgewählten Proben die Proteinexpression analysiert. Um den cytotoxischen Effekt 
nachzuweisen, wurden Zelllinien und mononukleare Zellen des periphären Bluts (PBMC) von 
gesunden Probanden und CLL Patienten mit Cannabinoiden in verschiedenen 
Konzentrationen inkubiert und mit Fludarabin verglichen. Die IC50 Werte wurden basierend 
auf Standardviabilitätstests kalkuliert.  
Beide Cannabinoidrezeptoren waren in der Studienkohorte überexprimiert. Während die 
CNR2 mRNA Expression mit keinem prognostischen Marker korrelierte, war eine hohe 
CNR1 Expression mit einem fortgeschrittenen Binet Stadium (p-Wert=0,049), unmutiertem 
IGHV (p-Wert=0,006) und erhöhter CD38 Expression (p-Wert=0,032), assoziiert. Zudem 
zeigten CNR1 hoch exprimierende Patienten ein kürzeres Gesamtüberleben (p-Wert=0,002) 
und behandlungsfreies Überleben (p-Wert=0,000). Die Porteinexpression konnte nicht 
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analysiert werden, da die kommerziell erhältlichen Antikörper sich als nicht spezifisch für 
CNR1 und CNR2 herausstellten. Bei der Inkubation der Tumorzelllinien MEC-1, MEC2 
(beide CLL), JURKAT (T-Zell akut Leukämie) und A-549 (Lungenkarzinom) mit (R)-(+)-
Methandamide, ACEA, (-)-Cannabidiol, JWH133, AM251 und AM630 mit verschiedenen 
Konzentrationen, konnte eine zeit- und konzentrationsabhängige Abnahme der Zellviabilität 
gezeigt werden. Zudem reagierten die Zelllinien, unterschiedlich sensibel, was nicht mit der 
mRNA Expression des CNR1 und CNR2 assoziiert war. Danach wurden die PBMC von CLL 
Patienten in Suspension- und in einem Cokulturmodell mit der Maus Fibroblasten Zelllinie 
M2-10B4 mit den Substanzen inkubiert. In dem Suspensionsmodell, zeigten die primären 
CLL Zellen eine ähnliche Anfälligkeit gegen ACEA, eine geringere gegen JWH133 und   
(-)-Cannabidiol und eine höhere Sensitivität gegen die anderen drei Cannabinoide. 
Das Cokulturmodell zeigte einen protektiven Effekt für die Cannabinoidinkubation, außer bei 
(R)-(+)-Methandamide und (-)-Cannabidiol. Diese hatten ebenfalls einen toxischen Effekt auf 
die M2-10B4. Außer (R)-(+)-Methandamide, hatten die Cannabinoide einen ähnlichen 
toxischen Effekt auf die gesunden Zellen.  
Im letzten Teil der Studie wurde das Mikroumfeld, besonders die CXCR4/CXCL12 Interaktion 
untersucht. Diese trägt zum Überleben von Leukämie Zellen bei und Cannabinoide wurden 
beschrieben, diese Interaktion in T-Zellen zu stören. Daher wurde der additive Effekt von 
Cannabinoiden mit Fludarabin untersucht und mit der Wirkung von AMD3100, einem CXCR4 
Inhibitor, verglichen. Es zeigte sich, dass Cannabinoide, im Vergleich zu AMD3100, einen 
geringeren Einfluss auf die Zellviabilität und nur einen geringen additiven Effekt mit 
Fludarabin hatten. Zuletzt wurde die Wirkung von Cannabinoiden auf die Migration von CLL 
Zellen, die CXCR4 exprimieren, zu CXCL12 getestet. Im Gegensatz zu AMD3100, hatten die 
Cannabinoide keinen signifikanten inhibierenden Einfluss auf die Migration. 
Bezogen auf den geringen Einfluss der Cannabinoide auf das Mikroumfeld in Bezug auf 
Überleben und Migration, sowie der ähnlichen toxischen Wirkung auf CLL und gesunde 
Zellen, scheinen Cannabinoide keine vielversprechende therapeutische Substanz in der CLL 
darzustellen. Obwohl die CNR2 Expression keinen prognostischen Wert ergab, konnten die 
CNR1 mRNA Expression als neuer prognostischer Marker gezeigt werden.  
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